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ABSTRACT 
Immune dysregulation is of importance in the pathophysiology underlying psychiatric 
disorders including major depression, bipolar disorder, and schizophrenia. 
Neurobiological alterations such as a dysregulated stress-hormonal axis and 
serotonergic alterations have been reported in suicide attempters at risk for subsequent 
suicide. Immune dysregulation in suicidal behavior is less well studied, but with some 
evidence for elevated proinflammatory cytokines and decreased levels of 
neurotrophins, such as brain-derived neurotrophic factor. The aim of this thesis was to 
study neuroinflammatory biomarkers with regard to suicidal behavior in patients with 
mood disorders. 
 
For the first part of this thesis (Studies I-III) we studied a high-risk cohort of patients 
with a recent suicide attempt. All were thoroughly assessed diagnostically and rated 
with regard to personality traits, severity of depression and suicidal intent. We did a 
follow-up on all patients regarding cause of death. 20 healthy controls were used for 
comparison. Patients were sampled for blood (n = 58) and cerebrospinal fluid (CSF) (n 
= 43). Samples were assayed using immune-based assay-systems for immune markers 
and growth factors.  
 
Seven patients who at follow-up, had completed suicide had lower plasma levels of 
vascular endothelial growth factor (VEGF). Furthermore, we found that the patients 
had lower CSF levels of both VEGF and interleukin- (IL-) 8 compared to the healthy 
comparison group. Lastly, we found that IL-6 levels in both plasma and CSF correlated 
with personality traits of impulsivity in suicide attempters.  
 
For the second part of this thesis (Study IV) we investigated the effects of physical 
activity on immune markers implied to be of importance in the pathophysiology of 
depression and suicidal behavior. The participants were completely healthy both 
somatically and psychiatrically. We studied the effects of an acute intensive exercise 
challenge during four days (n = 14), and a moderate exercise challenge during four 
weeks (n = 13). Paired sampling from blood and CSF before and after exercise 
intervention was compared. All rated mood before and after intervention.  
 
We found that CSF IL-8 was significantly elevated in both groups as a result of 
physical exercise. Serum IL-6 and IL-8 were significantly elevated in the total group, as 
well as IL-6 in the intensive group and IL-8 in the moderate group. We found no 
significant correlation between serum and CSF levels in the assayed analytes, 
suggesting that the effects of physical activity were segregated between the 
compartments. Furthermore, we found a negative correlation regarding mood ratings 
and CSF IL-8, suggesting relevance of CSF IL-8 as a state marker for mood. 
 
We propose that low VEGF may be a marker for treatment resistance and suicide 
risk, while high IL-6 seems to be related to impulsivity and violent methods of 
attempted suicide, both of which are important endophenotypes of suicidal 
behavior. Physical exercise is also an important confounder in immune biomarker 
studies.  
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1 INTRODUCTION 
 
1.1 SUICIDE AND SUICIDAL BEHAVIOR 
‘O happy dagger! 
This is thy sheath; there rust, and let me die.’ 
William Shakespeare, Romeo and Juliet, act 5, scene 3, 169-170. 
 
Suicidal behavior is as old as mankind. In literature the tragedy surrounding suicide is 
often depicted in a romantic and melodramatic way. The issue of suicide has constantly 
been subjected to philosophical and ethical considerations where religious and societal 
credos have heavily influenced our own views and ideas. Suicidal behavior is common 
and most people have in one way or another been affected by it. Therefore taking an 
interest in this topic and finding ways to better understand and prevent it is quite an 
obvious task. This has been my rationale when undertaking this scientific project, being 
a clinician working daily with psychiatric disorders and being interested more generally 
in human behavior.  
 
1.1.1 Scope 
Suicide and suicidal behavior constitutes a major health concern worldwide which 
leads not only to severe morbidity or premature death, but also to suffering and 
disability for the surrounding family and friends. To prevent suicide is a top priority for 
the clinician, but suicide risk assessment also constitutes one of the most complex 
psychiatric assessments (1–3). More objective measures are urgently needed. 
 
1.1.2 Suicide nomenclature 
A consensus nomenclature for understanding and communicating suicide and suicidal 
behavior in research separates suicide and suicidal behavior in three main groups (4).  
 
1. Completed suicide (CS). Death from injury that was self-inflicted and 
convincing evidence that the victim intended to kill himself/herself. 
2. Suicide attempt (SA). Injurious or non-injurious where the attempt was self-
inflicted and there is convincing evidence that the victim intended to kill 
himself/herself.  
3. Suicide ideation (SI). Expressed thoughts of wanting to engage in suicidal 
behavior. 
 
Suicide attempts are further classified as violent or nonviolent based on 
epidemiological findings that the method of attempt has important clinical implications 
and is predictive of a risk of future attempts and completed suicide (5,6). Self-
poisoning is considered to be a nonviolent attempt. All others (e.g., shooting, hanging, 
attempted drowning or gassing) are considered to be violent. 
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1.1.3  Epidemiology 
The global report on suicides from 2012 estimated the number of individuals for whom 
the cause of death is suicide to be more than 800,000. Suicide attempts are reported to 
be 10–20 times more frequent and, as opposed to completed suicide, to be more 
frequent among females (7). The global rate is about 11.4 per 100,000 individuals (15.0 
for males and 8.0 for females) (7). In the 15–29 age group, suicide is the second leading 
cause of death globally. In Sweden, 1524 people committed suicide in 2014 (1042 
males and 482 females), indicating a suicide rate of 19.0 per 100,000 individuals. In the 
15–24 age group, suicide is the most common cause of death in Sweden for both males 
and females (8).  
 
1.1.4 What causes suicidal behavior? 
Mental disorders are the most prominent risk factor for suicide or suicidal behavior 
with up to 90% of all victims having definable psychiatric diagnosis (1,9). For common 
mental disorders such as depression, bipolar disorder, schizophrenia, borderline 
personality disorder, anorexia nervosa and some substance-use disorders, the risk 
exceeds 10 times that of the general population (10). Major depressive episodes as part 
of either a major depressive or bipolar disorder account for at least half of suicides (9). 
However, suicide and suicidal behavior are highly complex and multi etiological and 
far from all patients with mental disorders commit suicide.   
 
1.2 RISK FACTORS FOR SUICIDAL BEHAVIOR 
Identified risk factors underlying suicidal behavior can be divided into so called 
proximal and distal factors, where proximal factors are precipitating events such as 
acute crisis or depressive disorder known to be a direct driving force towards suicidal 
behavior, and distal factors are underlying risk factors that predisposes any individual 
to suicidal behavior including early life adversity and heritable factors, also sometimes 
described in the stress-diathesis model for psychiatric disorders (9,11–13). 
 
1.2.1 Genetics 
Suicidal behavior runs in families, and twin-studies have estimated the heritability to be 
around 30-50% (9). However, suicidal behavior is complex and, on adjusting for other 
psychological conditions, the heritability estimate for suicide attempt is 17.4% and for 
suicidal ideation 36% (9). No specific gene linked to suicidal behavior has yet been 
identified, and genome-wide association studies (GWAS) have provided inconclusive 
results. Disorders generally decribed as having a complex underlying pathophysiology 
are frequently inconclusive in GWAS attempts, and it is not surprising that, so far, we 
have not seen more robust findings. Psychiatric genetics is however on the rise, with 
increasing sample sizes being assembled through collaborative research efforts such as 
the Psychiatric GWAS Consortium, and also with the help of better and increasingly 
less expensive technology doing, e.g., whole genome sequencing, where recent reports 
are encouraging (14–17).  
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1.2.2 Stress and the HPA axis 
The main regulator of homeostasis is the stress response system, mainly consisting of 
the hypothalamic-pituitary-adrenal (HPA) axis and the autonomic nervous system, 
constituted by the sympathetic nervous system (SNS) and its counteracting part, the 
parasympathetic nervous system (PNS) (18). Homeostasis is achieved by a constant 
regulation of physiological and behavioral responses challenged by external or internal 
stimuli (stressors). The SNS is the swift response system excreting norepinephrine 
(NE) from the locus coeruleus (LC) in response to stressors, while the HPA axis is the 
slower, but long-term regulator of stress homeostasis.  
 
The HPA axis, acts via hypothalamic excretion of corticotropin releasing hormone 
(CRH) and arginine vasopressin (AVP), which, in a synergistic manner, target the 
pituitary via the portal hypophyseal circulation (18).  From the pituitary gland 
adrenocorticotropic hormone (ACTH) is excreted reaching its target organ the adrenal 
glands that secrete glucorticoids (GCs). GCs are ubiquitous molecules, with a 
pleiotropic effect on multiple targets regulating bodily functions and the brain in 
response to stressors. GCs target glucocorticoid receptors (GRs) and mineralocorticoid 
receptors (MRs), which having different affinities, where GRs respond to higher 
concentrations of GC and MRs respond to lower concentrations, the MRs being 
important for the overall HPA axis tone. GC can cross the blood brain barrier and 
targets back at diverse brain regions, among others, the hypothalamus and pituitary, to 
resolve the stress response via a negative feedback loop mechanism (18). 
 
There is an intricate cross-talk between the immune system and the stress response 
system (19). An immune challenge triggers an acute inflammatory response, with an 
increase in proinflammatory cytokine activity. GC is also released during a stressor, 
such as infection, contributing, however, to a shift from proinflammatory domination 
with T helper (Th)1 to Th2 activity, thereby contributing to inflammation resolution via 
secretion of anti-inflammatory cytokines such as IL-4 and IL-10. Stress hormones may, 
however, in some settings, contribute to an increased release of proinflammatory 
cytokines, such as IL-1, IL-6, IL-8, and IL-18 or tumor necrosis factor- α (TNF-α) (19). 
The cross-talk between the stress response system and the immune system may, in 
some settings, malfunction, leading to deleterious chronic inflammatory conditions, 
characterized by an aberrant proinflammatory state and lack of inflammation 
resolution, contributing to the wide array of conditions that are clustered within the 
metabolic syndrome, such as atherosclerosis, certain cancers, autoimmune disease, and 
obesity, as well as depression (19). 
 
HPA axis dysregulation can be quantitatively assessed. The dexamethasone 
suppression test (DST) is a test in which cortisol is assessed the morning after the 
subject is provided with the glucocorticoid analogue, dexamethasone, given before 
bedtime. Displaying low levels of cortisol, suggests being a suppressor (hypoactive 
HPA axis) and high levels suggest being a nonsuppressor (hyperactive HPA axis). 
Melancholic depression is characterized by a hyperactive HPA axis whereas atypical 
depression seems to be more related to a hypoactive HPA axis tone (18). Severe stress-
reactions that are capable of inducing post traumatic stress disorder (PTSD), change the 
stress response system with a shift to a more depleted state as seen regarding NE 
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production within the LC (20) and a change in feedback mechanisms within the HPA 
toward a more hypoactive state (21). Regarding suicidal behavior there are 
inconsistencies, whereby some have reported associations between a hyperactive HPA 
axis, indicated by the DST, and an increased risk of completed suicide (22–25); 
however, there are also studies indicating that a hypoactive HPA axis is related to 
suicidal behavior (26,27).  
 
Hypothetically, these diverse links could be evidence of different phenotypes, 
characterized either by a blunted HPA axis that could be the result of repeated 
depressive episodes initially characterized by hyperactivity, but with long-term effect 
being a “worn-out” system with a more hypoactive HPA axis (26,27). The other 
phenotypical characteristic would be one with a more hyperactive HPA axis which also 
may be mediated by early-life adversity (ELA) (13), where constitutively high levels of 
cortisol contributes to symptoms of anxiety and may have debilitating effects on 
cognition. 
 
1.2.3 Early-life adversity (ELA) 
ELA has repeatedly been found to be a highly relevant risk factor underlying 
neuropsychiatric disorders, including suicidal behavior (28). ELA does not only impact 
the risk for neuropsychiatric disorders but also disorders related to the metabolic 
syndrome, such as diabetes or obesity (29). Disturbance of the HPA axis with HPA axis 
hyperactivity and affects on developmental processes such as personality traits may 
mediate the risks that follow ELA events (13).  
 
The evidence base is robust from animal studies (both rodents and primates) and 
studies in humans where e.g., epigenetic regulation (hypermethylation) is seen in the 
promoter region of the cortisol receptor in subjects who have experienced ELA (9). 
Further epigenetic regulation of the serotonin transporter and neutrophic factors, mainly 
brain-derived neurotrophic factor (BDNF) is evident from animal studies and a down-
regulation of mRNA coding for BDNF is seen in post-mortem studies on suicide 
victims with a history of ELA (9,29).  
 
1.2.4 The serotonergic system 
The serotonergic system has been studied in the context of psychiatric disorders for 
decades. Initially, findings by, e.g., Åsberg and collaborators (30,31) provided evidence 
for altered serotonergic neurotransmission in suicide attempters where low levels of the 
main serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA), was found in the 
CSF, and even though subsequent studies and a review questioned these results, a later 
meta-analysis could report low CSF 5-HIAA in attempters and also that low levels 
predicted future new attempts and completed suicide (32).  
 
Further studies, mostly postmortem, have extended the evidence for an altered 
serotonin neurotransmission in the brain, raising hopes that candidate gene studies 
would provide genetic risk markers for suicidal behavior (33). However, unfortunately, 
candidate gene studies with a focus on different alleles of tryptophan hydroxylase, 
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monoamine oxidase A (MAOA), or the serotonin transporter-linked polymorphic 
region (5-HTTPLR) have provided inconsistent results (13). 
 
1.2.5 Personality 
The concept of endophenotypes includes stable personality traits, which are believed to 
be highly genetically determined and relatively stable throughout the course of life. 
There is a long research tradition connecting personality traits as predisposing factors 
underlying the risk of psychiatric disorders including suicidal behavior. The concept of 
trait neuroticism with a disposition to negative emotion and anxiety is a strong risk 
factor for depressive disorder also predictive of recurrence and course (34,35).  
 
Regarding suicidal behavior, personality traits dominated by impulsivity and 
aggression are contextualized as important endophenotypes (36). The concept of 
impulsivity is a multifaceted construct, and the foremost domains that can be tested 
with neuropsychological test batteries are more robust and have a linkage to gene 
variants rather than results from personality inventories (37). These traits are the ones 
mostly replicated in studies on suicide risk, and seem to be especially important risk 
markers among younger subjects. Impulsivity and aggressiveness run in families, with 
evidence of strong heritability but an environmental influence is also found. The time-
frames for environmental influence seem to be mostly prominent during susceptible 
developmental phases such as in childhood and/or adolescence (36,38–42).  
 
There are population-based cohort studies that have assessed proinflammatory 
cytokines, mainly IL-6, and linked high levels to personality traits further associated 
with psychiatric and somatic morbidity (43–45). One of these studies could report an 
association between impulsivity measured with the NEO-PI-R (based on the five-factor 
model of personality) and higher levels of IL-6 (45) while another population-based 
study associated a more crude measure (white blood cell counts) and found an 
association with impulsivity (46). There are, however, associations between these traits 
and risk-taking habits such as smoking and between visceral fat accumulation and 
increased levels of proinflammatory cytokines (47), which could partly explain this 
link. Thus, impulsivity seems to correlate with both risk-taking habits and increased IL-
6 levels in the periphery and these associations may explain why there is an increased 
risk for morbidity and mortality connected to the same cytokine aberrations 
(43,45,48,49).  
 
When it comes to aggressive behavior, links have been reported between serotonergic 
regulation and, more recently, IL-6 and C-reactive protein (CRP) levels (37,50). A 
Swedish study has recently reported a connection between the acute-phase protein CRP 
and personality, with a genetic association. The authors reported an association 
between a CRP gene polymorphism with the personality domain Extraversion and its 
subscale Impulsiveness, measured with the Karolinska Scale of Personality (KSP) (51).  
 
1.3 ENDOPHENOTYPES AND RDOC 
As a consequence of disappointment in psychiatric research concerning translating 
promising results from preclinical studies into subsequent clinical studies, the core 
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concept of categorical psychiatric diagnostics has been called into question by the 
National Institute for Mental Health (NIMH). There take on this has been the so-called 
Research Domain Criteria (RDoC), emphasizing endophenotypic traits or biological 
substrates as more stable and valid constructs to bridge the gap from bench to bedside 
since diagnostic heterogeneity has long been appreciated and thought of as an important 
obstacle in research (52).   
 
The RDoC structure is completely agnostic regarding the Diagnostic and Statistical 
Manual of Mental Disorders (DSM) system, and the RDoC system is an ongoing 
framework that is constantly fueled by new findings in the field of biological psychiatry 
(52). The concept is also based on psychiatric disorders, including personality 
disorders, as being dimensional, rather than categorical. Since NIMH has promoted an 
emphasis on RDoC in research, there have been recent discussions about and criticism 
of both viewpoints, so perhaps, at the moment, keeping both perspectives may be the 
most relevant take while waiting for further knowledge to emerge from research (53–
55).  
 
1.4 BIOMARKERS IN PSYCHIATRY 
1.4.1 What do we mean by biomarkers? 
Biomarkers are biological variables that can have different features depending on what 
the biomarker is intended to describe. 
 
Davis and collaborators (56) propose a division of biomarkers into six different 
features;  
 
1. Biomarkers of risk, intended to predict an individual’s risk of developing any 
disorder; 
2. Biomarkers of diagnosis/trait, intended to be of help in the diagnostic process; 
3. Biomarkers of state/acuity, intended to measure the severity of the disorder; 
4. Biomarkers of stage, intended to reflect and measure staging in any disorder; 
5. Biomarkers of treatment response, intended to be of value for the clinician in 
predicting treatment response and individualized treatment; 
6. Biomarkers of prognosis, intended to predict the outcome for any individual 
(56).  
 
Furthermore, Pine and Leibenluft (57) argue that when thinking of biomarker research 
in psychiatry one cannot be satisfied with biomarkers that are simply predictive of 
treatment response and prognosis, but an intensified effort is needed to search for 
biomarkers closer to a mechanistic focus to align with research that has been 
instrumental to the great success that has been the case in other fields of medical 
research (57). While psychiatric research is inherently destined to be more complicated 
than, e.g., the same efforts in cardiology or infectious disease due to the complexity of 
the brain, a shift in focus on biomarkers that are narrow to mechanisms would be of 
great value for bringing leverage to the understanding and treatment of psychiatric 
disorders (57). 
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1.5 NEUROINFLAMMATION HYPOTHESIS OF DEPRESSION 
The current concept of the neuroinflammation hypothesis of depression was initially 
proposed by Smith in 1991, arguing for a role of macrophages in the pathophysiology 
of depression (58). However, even earlier, the role of infectious diseases and the 
immune system has always been a recurrent topic as in, e.g., the “focal infection 
theory” that had its highlight during the twenties and thirties as one overarching theory 
which argued that many systemic diseases, including schizophrenia and bipolar disease, 
had their origin in focal infections, primarily of dental origin (59).  
 
The neuroinflammation hypothesis postulates, based on the recognition of symptom 
overlap seen during states of infection (sickness behavior) and depression, such as 
depressed mood, fatigue, problems with concentration, lack of appetite, and 
insomnia, that an immune system dysregulation may be a pathophysiological 
mechanism underlying some cases of clinical depression (60–62).  
 
Based on this hypothesis, an increasing amount of preclinical and clinical research has 
focused on finding evidence that immune markers are involved and dysregulated, and 
indeed accumulating evidence has shown increased concentrations of proinflammatory 
cytokines (such as IL-6 and TNF-α) in major depressive disorder (MDD) and, more 
recently, in suicidal behavior (63–66).  
 
Corroborative evidence for the neuroinflammation hypothesis has also come from the 
clinical treatment that has been used for years for hepatitis C, in the form of interferon-
α, a powerful inducer of IL-6. This treatment has proved to be an experimental model 
for the induction of clinical depression, which is not distinguishable from a major 
depression, that is induced in up to 50% of treated patients, including the risk of 
suicidal behavior in some individuals (60,67,68). There is further evidence from post 
mortem studies reporting signs of increased mRNA levels of proinflammatory 
cytokines in the orbitofrontal cortex of suicide victims, as well as signs of microgliosis 
in suicide victims (69–71).  
 
1.6 NEUROTROPHIC HYPOTHESIS OF DEPRESSION 
The neurotrophic hypothesis of depression suggests that the pathophysiological 
pathway to depressive state also involves neurotrophic factors. Mainly, the idea is that 
neurotrophins important for cell survival, growth, maturation, synaptogenesis etc. 
(implying that they have an adverse effect on neuroplasticity) are affected and down-
regulated in response to, e.g., long-term stress, ELA via epigenetic regulation, acute 
stress or other genetic or environmental contributions to neurotrophin dysfunction (72–
74).  
 
BDNF has been most extensively studied to this end, but also VEGF, nerve growth 
factor (NGF) and fibroblast growth factor (FGF) are targeted in these investigations 
(75–77). Studies have proposed mechanisms for how induction of depressive states can 
be understood via cytokine activation of different pathways targeting the brain and 
affecting the HPA-axis, monoaminergic systems and growth factor expression 
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(72,74,78,79). Indeed, exercise can also affect neurotrophins with evidence of increased 
BDNF and VEGF (80,81) 
 
1.7 EXERCISE PHYSIOLOGY 
Physical activity is key in humans for maintaining health, homeostasis and preventing 
disease. Physical exercise (PE) is defined by the American College of Sports Medicine 
(ACSM), as “planned, structured and repetitive bodily movement done to improve or 
maintain one or more components of physical fitness” (82). There are several studies 
that report the effects of PE on different components of the immune system, where, 
e.g., the cytokine IL-6 is known to be released directly from the muscle fibers, and the 
systemic levels can increase 100-fold after a single prolonged session of physical 
exercise (83).  
 
The acute effects of PE are analogous to an acute stress-like reaction, with direct effects 
on the HPA axis and the SNS, resulting in the secretion of cortisol and epinephrine 
(83). The beneficial health effects of physical exercise are probably attributable to the 
long-term anti-inflammatory effects promoted by regular physical activity.  
 
Cortisol and epinephrine inhibit the release of TNF-α secreted by monocytes. IL-6 also 
contributes to this down regulation and even adds to a further secretion of cortisol. IL-6 
also stimulates the release of the anti-inflammatory cytokine IL-1 receptor antagonist 
(IL-1RA) from monocytes. PE also mobilizes regulatory T-cells (TReg) a major source 
of another anti-inflammatory cytokine, IL-10. Chemokine release in the periphery is 
also a known effect, where repeated increases in chemokines due to PE leads to a 
down-regulation of chemokine receptors and, as an effect of this, reduced tissue 
infiltration in the long term (83–85).  
 
1.8 THE ROLE OF CYTOKINES IN SUICIDAL BEHAVIOR 
The number of papers reporting on differences in cytokines related to suicidal behavior 
is increasing every year. Notwithstanding the increasing number, a certain amount of 
disappointment has arisen within the field of psychoneuroimmunology since the 
individual study results are difficult to replicate and inconsistencies are also common. 
Quite a few reviews and even meta-analyses have been published just during the last 
few years, mirroring the number of reports that have reached peer-reviewed journals 
(86–89).  
 
1.8.1 Cytokines in suicidal behavior 
There are several studies that have examined cytokines in relation to suicidal behavior. 
Mostly proinflammatory cytokines have been investigated where increased IL-1, IL-6, 
and TNF-α are reported to be the most consistent findings (86). However, low IL-2 and 
increased interferon-γ (IFN-γ) levels have also been reported (87–89). IL-6 is arguably 
the most promising biomarker, since IL-6 increase is reported not only in the periphery 
but also in the CSF and in some studies even distinguishing suicide attempters with 
depression, non-attempters with depression, and healthy controls (63,65).  
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For understanding of the mechanistic consequence of aberrant cytokine activity, an 
interesting connection with the kynurenine pathway is highlighted (90,91). 
Inflammation knowingly induces this pathway, where proinflammatory cytokines 
activate the rate-limiting enzyme indoleamine 2,3-deoxygenase (IDO) inducing 
tryptophan catabolism to kynurenine and reducing the production of serotonin (5-HT) 
(see Fig. 1) (74,92). The main catabolites in this pathway, kynurenic acid (KYNA) and 
quinolinic acid (QA), both have diverse effects directly modulating the main excitatory 
neurotransmitter system glutamate, which has also been directly associated with 
suicidal behavior in one study (74,90,92). 
 
 
Figure 1. Activation of the kynurenine pathway. Cytokines can induce the kynurenine pathway in 
inflammation conditions in both the periphery and the CNS. Pathway activation via IDO leads to 
tryptophan depletion (precursor also to 5-HT). In the periphery macrophages and dendritic cells can 
produce kynurenine, and in the central nervous system (CNS) microglia and astrocytes are involved in 
the farther downstream catabolism to CNS active KYNA and QA via KAT II or KMO and 3-HAO. 
KYNA can reduce glutamate release being an antagonist, and QA can increase glutamate release via 
NMDA-R activation, thus contributing to CNS excitotoxicity and eventually neurodegeneration. 
(Adapted from Haroon et al.) (74). 
 
1.9 THE ROLE OF NEUROTROPHINS IN DEPRESSION AND SUICIDAL 
BEHAVIOR 
1.9.1 Brain-derived neurotrophic factor (BDNF) 
BDNF, probably the most important neurotrophic factor, is also the most extensively 
studied marker in relation to depression and suicidal behavior. An exhaustive review 
concerning its role provides compelling evidence since peripheral BDNF levels are 
generally lower in suicide attempters, distinguishing even nonsuicidal depressed 
individuals, and low expression levels and mRNA levels are reported within the 
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prefrontal cortex and hippocampus in post-mortem studies, distinguishing suicide 
completers regardless of the psychiatric diagnosis (93). BDNF is also clearly regulated 
and affected by the HPA axis and stress and, in that respect, a further link with suicidal 
behavior could be contextualized (93). 
 
1.9.2 Vascular endothelial growth factor (VEGF) 
VEGF belongs to a family of proteins with different sources of origin and target effects 
(94). It was named VEGF since it was originally recognized as a key angiogenic 
protein vital for embryonic survival (95). VEGF-A, the prototypical member, has 
several isoforms in which two of the splice variants are predominant in the brain (94). 
There are also known single nucleotide polymorphisms which, in one study, have been 
shown to correlate with hippocampus morphology (96). The effect of VEGF is exerted 
mainly via the VEGF receptor-1 (VEGFR-1) and 2, VEGFR-2 being the most 
extensively studied (97). There is increasing evidence for VEGF to be neuroprotective 
and to have neurotrophic effects (94,98). Based further on studies of neuroprotective 
aspects, VEGF has also been suggested to be important in the pathophysiology of 
neurodegenerative disorders such as multiple sclerosis (MS) and amyotrophic lateral 
sclerosis (ALS), as well as Alzheimer’s disease (94,97). VEGF is also implicated in 
stress-related disorders and depression (73); however, prior to our reports, it has not 
been studied in relation to suicidal behavior. 
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2 AIMS 
The general aim of this thesis was to study whether neuroinflammatory biomarkers 
could be predictive of suicidal behavior and/or completed suicide. The first part of the 
thesis (studies I-III) was based on a well-characterized clinical sample of suicide 
attempters with a long-term follow-up in the Swedish national registers. The second 
part of the thesis (study IV) was based on a well-characterized sample of healthy 
participants without any history of psychiatric or somatic morbidity. 
 
Study I: A follow-up study of suicide attempters in which immune markers, mostly 
proinflammatory cytokines and growth factors, were assessed concerning their 
predictive value for completed suicide with the aim of identifying new inflammatory 
biomarkers for suicide prediction. 
 
Study II: A cross-sectional study in which we compare levels of proinflammatory 
cytokines and vascular endothelial growth factor in the CSF in suicide attempters and 
healthy controls. 
 
Study III: A cross-sectional study in which we assess the relationship between CSF 
and plasma interleukin-6, personality traits, and the method of attempted suicide in 
suicide attempters.  
 
Study IV: A longitudinal study on the effects on and variability of immunological 
biomarkers in healthy participants after two different physical exercise paradigms 
involving blood and CSF.   
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3 METHODS 
3.1 INCLUSION PROCEDURE 
3.1.1 Subjects, Studies I-III 
3.1.1.1 Study I 
 
For our first study, patients with a suicide attempt and having their clinical follow-up at 
the Psychiatric Clinic at the Karolinska University Hospital were asked to participate in 
a study on biological and psychological risk factors for suicidal behavior. The study 
protocol was reviewed and approved by the Regional Ethical Review Board in 
Stockholm (Dnr 93-211). All participants gave their written informed consent for the 
study. 
 
The study design is a follow-up study on a cohort of 58 suicide attempters (23 men; 
mean age, 39 years; SD = 12.7; range, 20–69 and 35 women; mean age, 36 years, SD = 
12; range, 18–68). Patient recruitment was carried out during the years 1993–1998. 
 
Inclusion criteria were as follows: 
• Age of 18 years or older 
• A recent suicide attempt (within a time limit of one month) 
• An adequate capacity to communicate verbally and in writing in the Swedish 
language. 
 
Exclusion criteria were as follows: 
• Psychotic disorder 
• Dementia 
• Mental retardation 
• Intravenous drug abuse 
 
Suicide attempt was defined as any nonfatal, self-injurious behavior with the intent to 
die. Eleven of the recruited patients (19%) had used a violent method when attempting 
suicide (6).  
 
The patients included were interviewed by a trained clinical psychiatrist using the 
Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental 
Disorders (SCID) (99) I, Research Version, when assessing the diagnosis in accord 
with the, at the time, current version of the DSM-III (99). The SCID II interview was 
used to assess the occurrence of axis II diagnoses. 
 
For the full cohort included in this study, the following diagnostic data were confirmed: 
93% had at least one current axis I psychiatric diagnosis; 
78% of the patients satisfied the criteria for some mood disorder, 7% for an adjustment 
disorder, and 3% for any anxiety disorder. One patient had a substance-use disorder and 
one an unspecified psychiatric disorder (not psychotic). A comorbid substance-use 
disorder was found in 24% of the cohort, where the majority had an alcohol-use 
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disorder. Patients that satisfied the criteria for some personality disorder amounted to 
39% of the cohort. Forty-seven patients (81%) were drug-free; 7 patients had been on 
antidepressant medication, mostly SRI.  
 
Table 1. Demographic and clinical data concerning the study population, survivors vs. 
victims. 
 
Variable  Surviving suicide attempters (n = 
51) 
Suicide victims (n = 
7) 
Age, mean ± SD 37 ± 12.3 37 ± 12.6 
Gender, male/female 19/32 4/3 
BMI, mean ± SD 24.3 ± 3.9 26.3 ± 3.1 
MADRS, median 
(IQR) 
17(10–23) 12.1(3–21) 
SIS, median (IQR) 15.7(11–21) 20.1(18–22) 
 
To determine outcome, defined as completed suicide on follow-up, we used the unique 
Swedish personal identification number and linked it to the National Swedish Cause of 
Death Register, regulated and controlled by the National Board of Health and Welfare 
(http://www.socialstyrelsen.se/register/dodsorsaksregistret). Before January 2009, 
seven of the original 58 patients had committed suicide. Suicides were ascertained from 
death certificates. Five of the patients had committed suicide within 6 years and two 
after 11 years from originally entering the study. 
 
Table 2. Descriptive statistics on the outcome measure, completed suicide. 
 
Variable Suicide completers (n = 7) 
Time to suicide (median, mean, range) 4 years, 6 years, 1.7–12.8 years 
Follow-up time (range) 11-15 years 
 
3.1.1.2 Studies II and III 
 
Patients included in Studies II and III were the same as those described in Study I with 
the exemption that only 43 out of the 58 patients also agreed to participate in the CSF 
component. Included in the CSF study were 43 suicide attempters (15 men; mean age, 
45 years; SD = 12.8; range, 22–69 and 28 women; mean age, 36 years; SD = 12.7; 
range 18–68). The same inclusion and exclusion criteria applied as described for Study 
I.  
 
The patients included did not receive psychotropic drugs of the antidepressant or 
antipsychotic class during a washout period (mean, 21 days; SD = 13.6) after the 
suicide attempt during admission to the ward. A few patients in the CSF sample (n = 7, 
16%) were treated prior to admission with antidepressant medication. The mean 
washout time for these patients was 34 days (SD = 14.1; range, 26–62 days).  
 
A diagnostic assessment was conducted as described for Study I. For this sample, 95 % 
of the participants had at least one current axis I psychiatric diagnosis; 79 % of patients 
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satisfied the criteria for mood disorders (unipolar, major depressive disorder, single 
episode or recurrent, bipolar disorder, depressed or dysthymic disorder), 7 % for 
adjustment disorder and 5 % for anxiety disorders, one patient had a substance-use 
disorder and one an unspecified psychiatric disorder (not psychotic). Twenty percent of 
the patients had a comorbid substance-use disorder (mostly alcohol-use disorder). 
Among axis II diagnoses, 37 % of the patients satisfied the criteria for a personality 
disorder.  
 
Somatic diagnoses in the sample: two patients had cardiovascular disease, three patients 
diabetes, one patient Crohn’s disease, one patient celiac disease, and four patients 
suffered from chronic pain, NUD.  
 
We used the Montgomery Åsberg Depression Rating Scale (MADRS) to assess the 
severity of depression (100). 
 
We also included 20 healthy male volunteers (mean age, 29 years; SD = 5.0; range, 22–
41). Healthy volunteers were all screened with an SCID interview conducted by a 
trained clinical psychiatrist to exclude any previous or current psychiatric disorders or 
any somatic conditions. All volunteers were screened for absence of psychiatric 
disorders in first-degree relatives. They were free from medication (total absence of 
psychotropic medication and no anti-inflammatory medication during the month 
previous to attendance), and they were also free from any substance-use disorder. 
 
Study flowchart: 
 
 
	Patients	are	recruited	within	the	catchment	region	of	the	Psychiatric	clinic	of	Karolinska	University	Hospital	between	1993-1998	
	
	81	suicide	attempters	agreed	to	participate	in	the	study			
	
	43/81	patients	had	reserve	CSF	sampling	
	
	58/81	patients	had	reserve	plasma	
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Table 3. Demographic and clinical data concerning the total study population. 
 
Variable Plasma 
Studies I 
and II 
CSF Study 
II 
CSF Study 
III* 
CSF healthy 
volunteers 
Suicide attempters n = 58 n = 43 n = 39 n = 20 
Age (years) mean ± 
SD, range 
37.2 ± 12.2, 
18–69 
39.0 ± 13.3, 
18–69 
38.6 ± 13.6, 
18–69 
28.9 ± 5.0, 
22–41 
Age (years) mean ± 
SD, range (male) 
39 ± 12.7, 
20–69 
45 ± 12.8, 
22–69 
45.6 ± 13.4, 
22–69 
28.9 ± 5.0, 
22–41 
Age (years) mean ± 
SD, range (female) 
36 ± 12, 18–
68 
36 ± 12.7, 
18–68 
35.5 ± 12.8, 
18–68 
– 
Gender 
(n=male)(%male) 
23, 40% 15, 35% 12, 31% 20, 100% 
BMI (kg/m2) mean, 
range 
24.6, 18.1–
32.8 
24.8, 18.2–
32.8 
24.7, 18.2–
32.8 
Not reported 
Depression as primary 
diagnosis 
44/58, 76% 33/43, 77% 30/39, 77% - 
Personality disorder 22/56**, 39 
%  
17/42**, 40 
% 
15/38**, 39 
%  
- 
Alcohol use disorder 14/58, 24% 9/43, 21% 7/39, 18% - 
Suicide method, 
violent (% yes) 
11/58, 19% 9/43, 21% 7/39, 18% - 
* The duplicates of four patient samples regarding IL-6 showed high variability and 
were therefore excluded from the analysis (see also the biological analysis section – 
Study III.) 
**In the plasma cohort two recordings, and, in the CSF cohort, one recording of 
personality disorders were missing. 
 
3.1.2 Subjects, Study IV 
For this study we used a longitudinal design in which healthy participants were 
recruited for one of two physical exercise conditions, four days in a row of intensive 
exercise or moderate thrice weekly sessions during four weeks, based on an assessment 
of their habitual physical exercise level.  
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All participants were instructed to refrain from all physical exercise activity seven days 
before biological sampling was performed. Following the baseline sampling, 
participants were instructed to start their exercise according to a preformed 
standardized protocol. The post-exercise sampling was performed the day after the 
participants had finished the exercise program. We used paired sampling from blood 
and cerebrospinal fluid. 
 
The study protocol was approved (Dnr 2014/1201-31/1) by the Regional Ethical 
Review Board in Stockholm, Sweden. All participants gave their written informed 
consent. 
 
The recruitment was conducted by advertising on local student campuses and in 
research laboratories, and also on the internet at websites targeted at college students. 
 
Inclusion criteria for the study were as follows: 
• Men and women aged 18 years or older; 
• Completely healthy with regard to both psychiatric and somatic disorders; 
• A habitual exercise level adequate for either of the exercise protocols. 
  
Exclusion criteria for the study were as follows: 
• An inadequate understanding of the study procedure and hence failure to 
provide informed consent;  
• Past or current major psychiatric or physical disorder (with an emphasis on 
autoimmune or inflammatory disorders);  
• Known heredity in first-degree relatives for severe psychiatric disorders, such 
as schizophrenia, bipolar disorder, major depression, and/or suicidal behavior; 
• Any current physical hindrance that precludes partaking in the physical 
exercise protocol. 
 
Participants contacted the researchers mainly through e-mail and were asked to provide 
a phone number. They were contacted initially for a telephone screening to determine 
their eligibility. Participants who were preliminarily determined to be eligible were 
booked for an inclusion visit with a trained clinical psychiatrist.  
 
At the inclusion visit, the participants were asked to provide a full medical history. The 
diagnostic psychiatric MINI interview (130) was used to screen for common 
psychiatric disorders. The MINI interview screens for both current and past episodes of 
common psychiatric disorders. Participants were also screened and assessed for their 
current health status and a basic clinical examination was performed. The participants 
were also asked to fill out the Patient Health Questionnaire 9 (PHQ-9) (102) before and 
after exercise. The questionnaire was supposed to be filled out on the day of biological 
sampling. The PHQ-9 is a frequently used screening tool for depressive symptoms, and 
it is also a tool for following depressive symptoms over time.  
 
Participants were deemed eligible for one of two physical exercise conditions. 
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Study flowchart: 
 
 
3.2 PSYCHOMETRIC INSTRUMENTS 
3.2.1 SCID I and II 
The Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental 
Disorders (SCID) is a semi-structured interview (99). The interview is supposed to be 
done by a trained clinician with the purpose of determining the occurrence of diagnoses 
according to the Diagnostic and Statistic Manual of Mental Disorders (DSM). The 
SCID interview can assess diagnoses within the axis I disorders (SCID I), which are the 
main psychiatric syndromes, and diagnoses within the axis 2 disorders (SCID II), 
which are personality disorders. For our study, SCID interviews were conducted to 
assess diagnoses according to the, at the time, current version of DSM, the DSM III 
(99). 
 
3.2.2 Montgomery-Åsberg Depression Rating Scale (MADRS) 
The Montgomery-Åsberg Depression Rating Scale (MADRS) was originally designed 
to be a rating scale that could be used in clinical research, since the rating was supposed 
to be sensitive to change. The MADRS consists in a clinician-administered interview 
52	par'cipants	
were	screened	
in	a	telephone	
interview.	
14	excluded.	
1	excluded	because	of	heredity.	
1	excluded	on	grounds	of	physical	
injury	a>er	ini'al	screening.	
12	withdrew	on	other	grounds;	e.g.	not	
'me	for	all	study	parts,	unwillingness	
to	rest	for	7	days,	or	reluctance	to	take	
part	in	the	lumbar	puncture	procedure.	
	
	
37	par'cipants	
were	fully	
assessed	at	
inclusion	visit.	
2	withdrew	a>er	baseline	
sampling.	
1	was	excluded	by	'me	of	planned	
sampling	because	of	subsequent	
ﬁnding	of	immunological	disorder.	
2	were	excluded	because	of	heredity	or	
were	found	to	have	had	previous	
psychiatric	disorder.	
13	fulﬁlled	all	
parts	of	the	
exercise	
protocol	and	
sampling.	
	
14	fulﬁlled	all	
parts	of	the	
exercise	
protocol	and	
sampling.	
19	were	found	
eligible	for	the	
intensive	
physical	
exercise	
protocol.	
16	were	found	
eligible	for	the	
moderate	
physical	
exercise	
protocol.	
2	withdrew	a>er	baseline	
sampling	because	of	suﬀering	
from	post	puncture	headache.	
1	because	of	sudden	soma'c	
illness	previous	to	sampling.	
1	because	of	vasovagal	
syncope	concomitant	with	the	
sampling.	
1	withdrew	on	other	grounds.	
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where the clinician assesses depressed mood from ten separate items. The scale is 
widely used in scientific research and pharmaceutical studies (100). 
 
3.2.3 Suicide Intent Scale (SIS) 
Beck’s Suicide Intent Scale (SIS) is an instrument consisting of 15 items. The different 
items are aimed at exploring the circumstances surrounding the suicide attempt. The 
items explore the patients’ feelings and appreciation of the lethality of the suicide 
attempt (103). A two-factor model of the SIS was developed (factor 1: Lethal intent 
subscale; and factor 2: Planning subscale) and was used in this thesis (104). 
 
3.2.4 Karolinska Scale of Personality 
The Karolinska Scale of Personality (KSP) is constructed as a self-assessment 
questionnaire. The incentives behind the construction were the idea of measuring 
personality traits that are thought of as vulnerability factors in biological research and 
to gain a further understanding of underlying mechanisms in psychiatric disorders 
(105). Its construct was initially developed within psychopathy research, but it was 
subsequently tested in healthy individuals and was also used in schizophrenia and 
suicidal behavior research (105).  
 
The original KSP inventory consists of 135 individual items that are grouped into 15 
subscales. Each item is provided, as a statement that can be responded to using a four-
point Likert-type scale ranging from “Does not apply at all” to “Applies completely”. 
The psychometric properties of the KSP and its subscales, with regard to test-retest 
long-term stability, internal consistency and predictive ability, are generally reported as 
acceptable (106,107). 
 
The KSP raw scores used in this thesis were transformed into T scores (population M = 
50, SD = 10) based on an age- and gender-stratified Swedish normative sample (105). 
There is a strong intercorrelation between individual subscales and, to reduce 
multicollinearity, scales have been grouped into a four-factor structure proposed by 
Gustavsson and collaborators (106) which includes:  
 
1) Neuroticism (including the subscales Socialization [negative loading], 
Somatic anxiety, Psychic anxiety, Muscular tension, Psychasthenia, 
Inhibition of aggression, Irritability, and Guilt);  
2) Psychoticism (including the subscales Detachment and Suspicion) 
3) Nonconformity (including the subscales Social desirability [negative], 
Indirect aggression, and Verbal aggression) 
4) Extraversion (including the subscales Impulsiveness and Monotony 
avoidance).  
 
This factor structure has been cross-validated by our research group, using a large 
cohort of suicide attempters, also including the patient sample used in Studies I–III 
(108) and is also used in this thesis (Study III). Our study focuses on the Extraversion 
factor, dominated by impulsiveness and sensation-seeking; see Table 4 for items 
included. 
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Table 4. Items from the KSP subscales, Impulsiveness and Monotony Avoidance. False 
(F) items indicate reverse scoring. Adapted from the Karolinska Scale of Personality 
(105). 
 
Item 
row 
KSP Impulsiveness items 
(8)  I have a tendency to act on the spur of the moment without really thinking 
ahead. 
(20) When I have to make a decision, I "sleep on it" before I decide. (F) 
 
(30)  I usually get so excited over new ideas and suggestions that I forget 
(48)  
 
I often throw myself too hastily into things. 
(62) I am a very particular person. (F) 
(68)  I think it is quite right to describe me as a person who takes things as they 
come. 
( 81)  I usually "talk before I think". 
(101)  When I'm about to make a decision, I usually make it quickly. 
(113)  
 
I take life easy. 
(127)  I consider myself an impulsive person. 
 
Item 
row 
KSP Monotony Avoidance items 
(2)  I am always keen on trying out things that are all new. 
(22) I like leading a quiet and organized life. (F) 
(28)  I prefer people who come up with exciting and unexpected activities. 
(44)  
 
I have an unusually great need for change. 
(54) I try to get to places where things really happen. 
(73)  I almost always have a desire for more action. 
(84)  In a way I like to do routine jobs. (F) 
(102)  I like doing things just for the thrill of it. 
(109)  
 
To be on the move, travelling, change and excitement - that's the kind of 
1ife I 1ike. 
(130)  When listening to the radio, I want it really loud, so that I can feel ”turned 
on.” 
 
 
The KSP has more recently been revised and the updated construct is known as the 
Swedish Universities Scale of Personality (SSP). The purpose of the SSP was to 
improve psychometric properties item homogeneity and face validity as compared to 
the original KSP. The length of the scale as well as the same amount of questions for 
each subscale were considered to improve practicality (109). The SSP subscales were 
also designed as a supposedly pool of scales where single scales could be used for 
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research properties. The SSP contains 13 scales, and all subscales contain seven 
questions with a four-point response format ranging from “does not apply at all” to 
“applies completely.” Normative data were calculated from a random sample of 741 
subjects living in Sweden. For Study IV, we included the SSP in the original inclusion 
procedure for future assessments on plausible correlations between personality traits 
and immune markers. 
 
3.2.5 MINI interview 
The MINI interview is a structured clinical interview developed to be used together 
with the clinician’s own assessment from the subject’s medical history. It is a short 
interview and has been validated with acceptable agreement toward a gold-standard 
SCID interview in assessing diagnoses according to the DSM or the International 
Classification of Diseases (ICD) (101). Because of its easiness of use and the short time 
for administration, it is widely used in clinical research. The interview determines the 
occurrence of affective disorders, anxiety disorders, substance use disorders, eating 
disorders or psychotic disturbances, previous or current. 
 
3.2.6 PHQ-9 
The Patient Health Questionnaire 9 (PHQ-9) is a tool intended to screen for depressive 
symptoms (102). It is also useful for following depressive symptoms over time. It 
measures nine symptom dimensions, based on current criteria for major depressive 
disorder. It also contains a tenth item that rates function. The score on each item ranges 
from 0 to 3, where 0 indicates no occurrence of a depressive symptom and 3 that the 
depressive symptom occurs most of the time, with only the nine symptom items being 
summed, with a possible total score ranging from 0 to 27 points. 
 
3.2.7 Borg’s rating of perceived exertion (The Borg Scale) 
The scale is commonly known as the Borg scale, named after the Swedish psychologist 
Gunnar Borg (110). Borg’s rating of perceived exertion (RPE scale) is an indicator of 
the accomplished level of peak exertion (110). The Borg scale has been validated and 
previous studies have reported very good levels of correlation with physiological 
variables of physical exertion (110); however, a recent meta-analysis concluded that the 
correlation levels might have been somewhat overrated previously and, in this report, 
the correlation is more moderate (0.62 for heart rate, 0.64 for %VO2max, and 0.72 for 
respiratory rate) (111). Recently, a study reported that there were no significant 
differences between physical exertion regulated by heart-rate monitoring or by using 
the RPE scale in a sample of healthy participants undertaking high-intensity interval 
training, suggesting that the RPE scale is a valid tool when prescribing exercise without 
clinical monitoring (112). 
 
  21 
3.3 BLOOD SAMPLING PROCEDURE 
3.3.1 Studies I–III 
Blood was sampled at the time of the suicide attempt during admission to the hospital. 
The sampling was performed after a night of fasting and bed rest. It was performed in 
the morning between 7:30 a.m. and 8:00 a.m.. 
 
Sampling was performed throughout the years 1993 to 1998, during which time the 
patients were recruited. It was done throughout every season. The study protocol 
assured that the same conditions were applied to all the samples. Blood was centrifuged 
within 5 min at room temperature (1000 × g during 10 min). Plasma was collected and 
stored at -80°C until measuring cytokine. The samples had never been thawed prior to 
the plasma immunoassay performed in 2010. 
 
3.3.2 Study IV 
Blood sampling was performed in a standardized manner between 7:30 a.m. and 9:00 
a.m. All participants were instructed to refrain from physical exercise for seven days 
prior to baseline sampling. Participants had fasted since midnight and came to the clinic 
after a night of bed rest. Blood was drawn and collected in a BD vacutainer serum tube 
(9 ml) and allowed to clot for 30 minutes at room temperature before being centrifuged 
within an hour (2900 rpm/1692 rcf for 15 minutes). Due to an administrative error 
during sampling, three of the participants had no stored serum; therefore, the serum 
group consists of 24 participants, 12 in each exercise group. The same conditions were 
applied to all the samples. The aliquot samples had never been thawed prior to the 
analysis. Samples were collected between February and July, 2015.  
 
3.4 CSF SAMPLING PROCEDURE 
3.4.1 Studies II–III 
Lumbar punctures were performed at the end of the washout period in a standardized 
manner, after blood sampling, between 8:00 a.m. and 9:00 a.m.. Sampling was 
performed after a night of fasting and bed rest. CSF samples were collected from all 
seasons throughout the year between 1993 and 1998. A volume of 12 ml of CSF was 
drawn with the patient in the sitting position, the needle being inserted between lumbar 
vertebrae IV and V. The CSF was immediately centrifuged and stored at  
-80°C until analyzed. The aliquot CSF samples had never been thawed prior to the 
immunoassay done in November, 2011. 
 
3.4.2 Study IV 
Lumbar punctures were performed in a standardized manner between 7:30 a.m. and 
9:00 a.m.. All participants were instructed to refrain from physical exercise for seven 
days prior to baseline sampling. Participants had been fasting since midnight and came 
to the clinic after a night of bed rest. A volume of 25 ml of CSF was withdrawn with 
the patient in the sitting or lying position. An “atraumatic” Sprotte needle (22G, 0.70 
mm, 70 mm or 90 mm) was used for sampling, the needle being inserted between 
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lumbar vertebrae III and IV or IV and V. The CSF was immediately centrifuged and 
the supernatant stored at -80 degrees C until analyzed. The aliquoted samples had never 
been thawed prior to the analysis. Samples were collected between February and July, 
2015. 
 
3.5 BIOLOGICAL ANALYSIS 
3.5.1 Study I: Randox Biochip 
For the first study, we used a high-throughput automated biochip immunoassay system 
developed by Randox Laboratories Ltd (Crumlin, UK). The biochip has been 
extensively validated against gold-standard ELISA for several common cytokines 
(113).  
 
Using a multiplex panel, we investigated the following cytokines and growth factors: 
IL-1-α, IL1-β, IL-2, IL-4, IL-6, IL-8, IL-10, IFN-ɣ, TNF-α, Monocyte Chemotactic 
Protein-1 (MCP-1), Epidermal Growth Factor (EGF), and VEGF.  
 
The Biochip Array technology is used to perform simultaneous quantitative detections 
of multiple analytes from a single sample, a so-called multiplex. The technology 
involves the Randox Biochip, a solid-state device containing an array of discrete test 
regions of immobilized antibodies specific to different cytokines and growth factors. A 
sandwich chemiluminescent immunoassay is employed for the cytokine array. The 
light signal generated from each of the test regions on the biochip is detected using 
digital imaging technology and the concentration of analyte present in a patient sample 
or control was calculated from a calibration curve.  
 
All the values obtained in this study were in the range of the standard/calibration curve. 
Since this was the high-sensitivity kit, each calibration begins at 0 pg/ml. The inter-, 
intra-assay variation is less than 10% according to the manufacturer. Quality control 
procedures were all implemented in the cytokine profiles that had passed predefined 
acceptance criteria to guarantee a high degree of precision. 
 
3.5.2 Study II: Mesoscale 
3.5.2.1 VEGF 
Samples were run on two MSD Human VEGF 96-well plates (K151BMC-1; 
Gaithersburg, MD) and the results were pooled. The assay calibrator was diluted 
according to the manufacturer’s recommendation, except for for the standard curve 
starting at 1000 pg/µL. 
 
Each well was blocked with 150 µL Blocker C (provided) for 2h at room temperature 
(RT) on an orbital shaker (400 rpm). The plates were washed three times with 150 
µL/well of Phosphate Buffered Saline + 0.05% Tween-20 (PBS-T). Diluent 7 
(provided) was added at 25 µL/well. Calibrator, samples, and controls were added at 25 
µL/well. The plate was sealed and incubated overnight at 4°C on an orbital shaker (400 
rpm). At the end of the incubation, the wells were washed three times with PBS-T. 
After the last wash, detection antibody was added at 25 µL/well. The plate was sealed 
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and incubated in the dark for 2 h at room temperature on an orbital shaker (400 rpm). 
At the end of the incubation, the plate was washed 3 times as before. 150 µl of the 
MSD 1X Read Buffer T was added to each well and the plate was measured 
immediately on the MSD Sector Imager 2400 plate reader. 
 
3.5.2.2 IL-6 and IL-8 
Samples were run on two MSD Human Pro-inflammatory-4 II Ultra-Sensitive 96-well 
plates (K15025C-1). The samples were run according to the manufacturer’s 
recommendation, with the following exceptions: standard points starting at 1000 pg/µL. 
Calibrator, samples and controls were incubated overnight at 4°C.  
 
3.5.3 Study III: Mesoscale 
The samples were analyzed using two MSD Human Pro-inflammatory-4 II Ultra-
Sensitive 96-well plates (K15025C-1). The samples were analyzed according to the 
manufacturer’s recommendations, with the following exceptions: The standard points 
started at 1000 pg/µL; and the calibrator, samples and controls were incubated 
overnight at 4°C. The duplicates of four patient samples regarding IL-6 showed high 
variability and were therefore excluded from the analysis. A total of 39 patients are 
included in the CSF Results and Table sections. The inter-assay variation was 7.3%, 
and the intra-assay variations were 7.9% and 6.6%, respectively.  
 
3.5.4 Study IV: Cytometric bead-array (CBA) 
Bead-based flow cytometric arrays have the capability to simultaneously and 
quantitatively measure multiple antigens or antibodies in small volumes of biological 
fluid. This technology is suitable when attempting to assess immune cell expression, 
such as cytokines and chemokines. The technology utilizes individual beads with an 
individual fluorescent characteristic for the detector to identify. The beads have their 
own individual set-up of analytes that can be assayed (114). There are two 
commercially available instruments that utilize this technology developed by Luminex 
and BD Biosciences. For this study, we used the instrument by BD Biosciences that 
also developed a flexible bead assay kit which lets the user customize the analytes that 
can be assessed in a multiplexed fashion (114).  
 
3.5.4.1 CSF assay 
Expecting the levels of cytokines to be low in CSF, the CBA Enhanced Sensitivity Flex 
Set (BD, San Jose, CA, USA) was used for IL-2, IL-6, IL-8, IL-10, TNF-α, and IFN-γ. 
VEGF was analyzed according to the protocol and kit described for serum, although 
without dilution using 50 µL CSF, as done with the other CSF samples. All samples (n 
= 54) were run in duplicates. Lyophilized standards for all analytes were pooled in a 
polypropylene tube and reconstituted with 4 mL of assay diluent for 15 minutes. The 
standard was serially diluted 1:3, 1:9 through 1:729 with an initial 40 µL reconstituted 
standard in 460 µL of assay diluent for the top standard and 400 µL of assay diluent in 
each tube, including a standard-free negative control. Capture beads were added to the 
sample and standard wells and incubated for 2 hours at RT. Detection reagents were 
pooled and diluted to 20 µL per test and incubated for 2 hours at RT. The plates were 
washed twice by adding 200 µL wash buffer and centrifuging at 500 rpm for 5 minutes 
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with unforced deceleration and discarding the supernatant. An Enhanced Sensitivity 
Detection Reagent (100 µL per test) was added and left to incubate for 1 hour at RT. 
Plates were centrifuged and the supernatant was discarded once more as described. 
Lastly, 150 µL of wash buffer was added and the plates were placed on a shaker to 
resuspend the beads before sample acquisition. 
 
The samples were acquired using Beckman Coulter CyAn ADP (FACS; Beckman 
Coulter, CA, USA) at 488 and 635 nm and 300 events per bead and analyzed with the 
FCAP Array v3.0 software (Beckman Coulter, CA, USA). 
 
3.5.4.2 Serum assay 
BD CBA Human Soluble Protein Flex Set (BD, San Jose, CA, USA) was used for 
quantifying serum levels of IL-2, IL-6, IL-8, IL-10, TNF-α, and IFN-γ. The protocol 
was the same as for CSF, with the exception of a serum dilution of 1:4 for all samples.  
 
VEGF was analyzed from serum and was thawed and diluted 1:5 with assay diluent 
from the BD CBA Human Soluble Protein Master Buffer Kit. All samples (n = 54) 
were run in duplicates. Lyophilized standards for all analytes were pooled in a 
polypropylene tube and reconstituted with 4 mL of assay diluent for 15 minutes. The 
standard was serially diluted 1:2, 1:4 through 1:256 with an initial 500 µL of top 
standard transferred and 500 µL of assay diluent in each tube including a standard-free 
negative control. Capture beads were pooled, washed with 0.5 mL of wash buffer and 
centrifuged at 200 g for 5 minutes before aspirating the supernatant, and diluted in 
Capture Bead Diluent for a final volume of 50 µL per test. Capture beads were added to 
sample and standard wells and incubated for 1 hour at RT. Detection reagents were also 
pooled, diluted with Detection Reagent Diluent for a volume of 50 µL per test and 
incubated for 2 hours at RT. After adding 150 µL of wash buffer and centrifuging at 
500 rpm for 5 minutes (unforced deceleration), the supernatant was discarded and the 
beads were resuspended with 300 µL wash buffer. 
 
3.6 STATISTICAL ANALYSIS 
3.6.1 Study I 
The JMP 12 (SAS Institute, Inc., Cary, NC, USA) statistical package for Mac OS X 
was used for all statistical analyses. Figures presented were done with Stata/SE 12.1 for 
Mac. 
 
We identified two male patients as multivariate outliers by using the Mahalanobis 
distance (115). The exclusion of these individuals did not affect the results, and they 
were included in all statistical analyses. Patient characteristics were described by using 
the mean, the median and the range for quantitative variables. The Shapiro–Wilk test 
was used to test data regarding normal distribution. Data for all cytokines displayed a 
skewness above 2. We used nonparametric statistics (Kruskal–Wallis test) in 
continuous variables for between-group comparisons; suicide victims vs. survivors.  
 
Tests of nonparametric correlations were performed using Spearman’s ρ. Regression 
analysis was performed to control for age, gender and body mass index (BMI). 
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Pearson’s chi-square and Fisher's exact test were used for cross tabulations of 
categorical variables.  
 
Alpha was set at 0.05.  
 
3.6.2 Study II 
The JMP 12 was used for all statistical analyses. Figures presented were done with 
Stata/SE 12.1. 
 
We identified one patient as being both a univariate outlier (3.5 S.D. above the mean of 
the patients) and a multivariate outlier calculated using the Mahalanobis distance (115). 
This patient was excluded from all statistical analyses.  
 
Both CSF VEGF and IL-8 levels were normally distributed, whereas CSF IL-6 was not 
normally distributed. The potential effect of the confounding factors was tested in 
linear regression models. The model consisted of age, gender, BMI, a comorbid 
diagnosis of personality disorder and alcohol-use disorder. Only age was a significant 
predictor of CSF VEGF levels in the model (t = 2.14, p = 0.04); other p values ranged 
between 0.25 and 0.82. The group comparisons were adjusted for age using linear 
regression.  
 
With regard to plasma levels of VEGF and IL-8, one patient was identified as being 
both a univariate outlier (6 SD above the mean of the patients) and a multivariate 
outlier calculated using the Mahalanobis distance. This patient was excluded from the 
correlation analysis between CSF and plasma levels of VEGF and IL-8. Tests of 
parametric correlations were performed using Pearson's r. Tests of nonparametric 
correlations were performed using Spearman’s ρ. 
 
Alpha was set at 0.05.  
 
3.6.3 Study III 
The JMP 12 was used for all statistical analyses. Figures presented were done with 
Stata/SE 12.1. 
 
The plasma and CSF IL-6 data were tested for normality using the Shapiro-Wilk test. 
To reduce skewness to the right, all of the data were logarithmically transformed for 
additional analysis. The quantitative population characteristics were described using 
means, standard errors, and quantiles.  
 
The potential effect of confounds with regard to the log of plasma IL-6 was tested using 
a multivariate linear regression model. The models consisted of age, gender, BMI, 
depression severity (as measured by the MADRS), a comorbid diagnosis of personality 
disorder, and alcohol-use disorder. Only age significantly predicted plasma IL-6 in the 
model (t = 3.8, p = 0.0004); other p values ranged between 0.26 and 0.86. Furthermore, 
adding a diagnosis of somatic comorbidity to a separate model with age and 
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extraversion as predictors did not affect the significance of the model, and somatic 
comorbidity did not predict plasma IL-6 (p = 0.94).  
 
Similarly, the potential confound effect for the log of CSF IL-6 was tested using the 
same parameters; however, no significance was found for the tested confounds, and the 
p values ranged between 0.09 and 0.95. The sample storage time was not significantly 
correlated with IL-6 levels (p = 0.96 for plasma, p = 0.43 for CSF). 
 
Tests of parametric correlations were performed using Pearson’s r. Tests of non-
parametric correlations were performed using Spearman’s ρ. 
 
A standard forced multiple regression analysis tested the association between plasma 
IL-6 levels and KSP personality factors, with the former as the dependent variable and 
the latter (neuroticism, psychoticism, extraversion, and nonconformity) and age as the 
independent variables. Group differences (violent vs. non-violent suicide attempts) 
were computed using one-way ANOVAs for the continuous variables. 
 
Alpha was set at 0.05. 
 
3.6.4 Study IV 
The JMP 12 statistical package for Mac OS X was used for all statistical analyses.  
 
The assayed variables were heavily skewed and tested for normality using the Shapiro-
Wilk test. Only post-CSF IL-8 was normally distributed (p = 0.44). The quantitative 
sample characteristics were described using means, standard deviations, and range. The 
potential effect of confounds with regard to the assayed variables was tested using a 
multivariate regression model. The models consisted of age, gender, and BMI. No 
effect for confounds was determined to be significant. P values ranged between 0.21 
and 0.92. Nonparametric statistics (Kruskal–Wallis test) were used when comparing 
continuous variables across groups pre-intervention (High vs. Low/Moderate habitual 
exercise levels). Since analytes were not normally distributed, tests of matched 
variables differences in means pre- and post-intervention in the total group and across 
groups (intensive or moderate exercise group) were performed using nonparametric 
statistics (Wilcoxon matched-pair signed-rank test). Tests of nonparametric correlations 
were performed using Spearman’s ρ. 
 
Alpha was set at 0.05.  
 
3.7 ETHICAL APPROVAL 
3.7.1 Ethical considerations 
Studies conducted on clinical populations require careful ethical considerations. For 
this clinical study, we recruited patients with a recent suicide attempt who were also 
taken to an inpatient service for further psychiatric treatment. The process of lumbar 
puncture is an invasive procedure with known side effects and, at the moment, is not 
done in routine psychiatric care. Furthermore, being part of this study meant that the 
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patients were also thoroughly assessed clinically using an extensive clinical assessment 
battery, a procedure potentially contributing to more distress.  
 
We believe, however, that the value in the short run for the included patients consisted 
in the extensive, non-routinely conducted assessment with plausible benefits for the 
patients during follow-up care, as well as their having had an extensive medical 
assessment since routine variables were also assayed in the biological samples 
provided. We also believe that, in the long run, again from the patients’ perspective, the 
value of investigating the intrathecal compartment in this context is of marked benefit 
since the CSF would arguably be a better fluid for investigating the milieu surrounding 
the brain. By doing this, the patients will hopefully contribute to our further 
understanding of the complex biological pathophysiology underlying these debilitating 
disorders. 
 
3.7.2 Studies I-III 
These studies were conducted in accordance with the Declaration of Helsinki. The 
study protocols were approved (Dnr 93-211) by the Regional Ethical Review Board in 
Stockholm, Sweden. 
 
3.7.3 Study IV 
The study was conducted in accordance with the Declaration of Helsinki. The study 
protocols were approved (Dnr 2014/1201-31/1) by the Regional Ethical Review Board 
in Stockholm, Sweden. 
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4 RESULTS AND DISCUSSION 
 
4.1 STUDY I 
4.1.1 Cytokines and descriptive statistics 
Patient age and BMI correlated positively with plasma IL-6 levels (Spearman’s ρ = 
0.44 for age; Spearman’s ρ = 0.32 for BMI) and tended to correlate positively with 
VEGF levels (Spearman’s ρ = 0.25 for age; Spearman’s ρ = 0.18 for BMI). The 
correlation between storage time and VEGF levels was not significant (Spearman’s ρ = 
–0.03, p = 0.81). There was no significant effect of the degree of depression (MADRS 
score), comorbid diagnosis of a personality disorder, or a substance-use disorder on the 
cytokine levels in the suicide attempters. 
 
4.1.2 Cytokine levels and suicide risk 
Seven suicides (12 %) occurred during the follow-up time: three females (8.7 %) and 
four males (17 %). The major finding was that the mean VEGF distinguished between 
suicide completers (mean + SE) (14.6 ± 7 pg/mL) and survivors (24.9 ± 2.6 pg/mL) (n 
= 58, p = 0.033, Kruskal–Wallis test) (Table 5).  
 
Table 5. Nonparametric test for associations between inflammation markers in 
survivors vs. completers. 
 
Cytokines mean ± 
SD pg/mL 
Suicide attempters 
(n=51) 
Suicide completers 
(n=7) 
P value 
IL 1-α 0.14 ± 0.14 0.12 ± 0.04 0.52 
IL1-β 1.0 ± 1.88 0.39 ± 0.49 0.33 
IL-2 1.16 ± 1.33 0.44 ± 0.84 0.037* 
IL-4 1.61 ± 1.22 1.28 ± 0.60 0.90 
IL-6 1.38 ± 0.97 1.82 ± 2.84 0.30 
IL-8 2.20 ± 1.78 1.80 ± 1.23 0.75 
IL-10 0.52 ± 0.48 3.27 ± 7.38 0.18 
VEGF 24.9 ± 19.5 14.58 ± 6.03 0.033* 
IFN-ɣ 1.04 ± 0.93 1.69 ± 1.51 0.063 
TNF-α 3.07 ± 1.58 2.48 ± 1.36 0.11 
MCP-1 136.59 ± 84.70 112.37 ± 6.51 0.53 
EGF 24.29 ± 17.97 24.97 ± 21.55 0.88 
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Figure 2. Box plot on log plasma VEGF at baseline across suicide completers vs. 
survivors upon follow-up. 
 
When age, gender, and BMI were used as covariates in a regression analysis, the 
regression model with VEGF was significant (n = 58, χ2 = 10, df = 4, p = 0.040). VEGF 
was a significant predictor of suicide (p = 0.045). Suicide victims had lower levels of 
IL-2 (Mean + SE) (0.4 ± 0.49 pg/mL) compared to survivors (1.2 ± 0.18 pg/mL) (n = 
58, p = 0.037, Kruskal-Wallis test). When age, gender, and BMI were used as 
covariates in a regression analysis, the regression model with IL-2 did not remain 
significant (n = 58, χ2 = 6.8, df = 4, p = 0.14). IL-2 showed a trend to being a predictor 
of suicide (p = 0.099). There was a trend toward higher IFN-ɣ levels in suicide victims 
compared to survivors (n = 58, p = 0.063, Kruskal–Wallis test). 
 
4.1.3 Cytokines and suicide intent 
Plasma VEGF tended to be negatively correlated with the Planning subscale of SIS 
(Spearman’s ρ = –0.24, p = 0.076). Plasma IFN-ɣ showed a significant positive 
correlation with SIS (Spearman’s ρ = 0.26, p = 0.048) and with the Planning subscale 
(Spearman’s ρ = 0.28, p = 0.038). IL-2 did not correlate with suicide intent.  
 
4.1.4 Discussion 
The rationale for the first study was to determine how proinflammatory cytokines could 
be predictive and how they varied between suicide victims vs. survivors in a cohort of 
suicide attempters. We approached this question by using a longitudinal design where 
we conducted a follow-up regarding cause of death with our outcome measure being 
completed suicide.  
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The main finding in this study was that patients with a recent suicide attempt who, at 
follow-up had committed suicide, had significantly lower plasma levels of VEGF at the 
time of inclusion. We could also report that suicide victims had lower levels of IL-2, a 
finding that however did not reach significance in our regression model. Furthermore 
IFN-ɣ levels tended to be higher in suicide victims. VEGF also tended to be negatively 
correlated with the planning subscale of the SIS, i.e., the more planned the suicide 
attempt, the lower the levels of VEGF.  
 
The main finding regarding low plasma VEGF levels predicting complete suicide is 
interesting in the context of the neurotrophic hypothesis of depression and the 
theoretical discussion regarding VEGF as a possible trait marker for treatment 
resistance as suggested by, for example, Halaris and collaborators. Namely, while low 
VEGF levels at baseline in this sample, might constitute a more severe subgroup even 
within this high-risk cohort of suicide attempters, they might explain why these 
subjects had a less fortunate outcome.  
 
Furthermore, our other findings regarding IL-2 and IFN-ɣ are in line with other 
research in this field (87–89). Low peripheral levels of IL-2 have been reported 
previously, and so have increased peripheral levels of soluble IL-2 receptor (sIL-2R) in 
suicide attempters (116). Since IL-2 and sIL-2R binds into a complex that is 
internalized with lysosome degradation, elevated sIL-2R may explain the low levels 
seen in suicide attempters compared to controls in some studies (117,118).  
 
Based on the above, we could propose a role for plasma VEGF as a plausibly relevant 
new biomarker for both prediction and as a trait marker. However, this obviously needs 
to be replicated in future studies. 
 
4.2 STUDY II 
4.2.1 CSF immune markers and suicide attempters 
CSF VEGF and IL-8 levels were significantly lower in suicide attempters (VEGF 
mean, 3.7; pg/mL, IL-8 mean, 17.1 pg/mL) compared to controls (VEGF mean, 5.0 
pg/mL; IL-8 mean, 25.6 pg/mL) (t-ratio = -3.76; p = 0.0004; t-ratio = -5.82; p <0.0001, 
both adjusted for age) (Fig. 3a and 3b).  
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Figure 3a. Box plot on CSF VEGF in suicide attempters and healthy controls. 
 
 
Figure 3b. Box plot on CSF IL-8 in suicide attempters and healthy controls 
 
4.2.2 CSF VEGF and depression severity 
CSF VEGF levels showed a significant negative correlation with depression severity as 
measured with the MADRS (r = -0.31; p = 0.049) (Fig. 4). A correlation analysis of 
CSF IL-8 levels and MADRS was not significant (r = -0.13, p = 0.40).  
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Figure 4. Correlation between CSF VEGF and MADRS. 
 
4.2.3 Correlation between immune markers 
In suicide attempters, VEGF tended to be positively correlated with IL-8 levels (r = 
0.29, p = 0.066). Interestingly, the levels of CSF VEGF and IL-8 did not correlate with 
plasma levels of VEGF and IL-8 in suicide attempters (Spearman’s ρ = 0.04, p = 0.80; 
Spearman’s ρ = 0.06, p = 0.70). CSF IL-6 levels did not differ in suicide attempters 
(mean 1.1 pg/mL) compared to controls (0.9 pg/ml) (t-ratio = 0.91, p = 0.37, adjusted 
for age).  
 
4.2.4 Discussion 
The rationale for the second study was to determine cytokines and VEGF in the CSF in 
suicide attempters compared to healthy controls, in order both to assess whether we in 
our sample could replicate results from previous studies, and also whether potentially 
new findings in our sample could generate new information regarding biomarkers in 
suicide research.  
 
The main finding was that suicide attempters had lower levels of VEGF and IL-8 in the 
CSF as compared to healthy controls. VEGF and IL-8 levels in the CSF did not 
correlate with peripheral levels. In our study, CSF IL-6 was not higher in suicide 
attempters compared to controls, inconsistent with the findings by Lindqvist and 
collaborators (63).  
 
Our results indicate that low CSF VEGF and IL-8, might in this context be biomarkers 
regarding risk for suicide attempt. This finding is not readily interpretable, but 
speculatively, the low CSF VEGF levels could indicate a lack of neurotrophic support. 
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The lack of correlation between compartments suggests that this plausible down-
regulation is segregated from the peripheral source. However, we did not include other 
neurotrophins or markers regarding the HPA axis in our assay, which excludes the 
possibility to determine whether this is selective for VEGF. We can neither rule out the 
possibility that our finding represents an epiphenomenon, which also could be the case 
regarding the finding relating to IL-8. 
 
Chemokines are immune-competent proteins that signal to the immune system to 
recruit immune cells to the site of action during an immune challenge. IL-8 is one of 
the best known chemokines (about 50 human chemokines are described) that is 
important in recruiting neutrophils to target sites. IL-8 also seems to be of importance 
as a vascular signal together with VEGF and also when it comes to inflammation 
resolution, depending on the circulating levels of IL-8. High levels are reported to be 
considered anti-inflammatory, inhibiting further adhesion of neutrophils and repeated 
activation of IL-8 seems to attenuate the inflammation response through receptor down-
regulation (119). IL-8 is also a pleiotropic molecule and has been reported to be 
proangiogenic, whereby an association has been previously reported between IL-8 and 
an increase in VEGF and its receptor VEGFR-2 via a Nuclear Factor kappa B (NFkB)-
mediated pathway (120).   
 
In psychiatric research, the reports concerning IL-8 vary between studies. Low 
peripheral IL-8 levels were previously associated with depression in a population-based 
sample (121). IL-8 in the CSF was previously described as being positively correlated 
with alexithymia and anxiety in patients with a non-inflammatory neurological disorder 
(122). A majority of the patients included in that study had a diagnosis of neurological 
pain, which could explain partly, the reported association with elevated chemokine 
levels. After our report, IL-8 has also been reported to be negatively correlated to 
anxiety in a cohort of suicide attempters (123). This study raises further questions about 
the role of IL-8 as a marker for a phenotypic subgroup with comorbid anxiety, i.e. 
symptoms that increase the clinical severity and constitute a statistical risk for 
recurrence of suicidal behavior (124). 
 
Based on this study, a role for both CSF VEGF and IL-8 as relevant biomarkers for 
suicidal behavior could be suggested. Whether this is a state or trait marker, or a marker 
that may distinguish suicide attempters from other psychiatrically relevant comparison 
groups can not be ruled out and needs further clarification in future studies. These 
markers are part of innate immunity, suggesting that mechanisms within innate 
immunity should be more thoroughly elucidated. 
 
4.3 STUDY III 
4.3.1 Plasma and CSF IL-6 levels 
The plasma and CSF IL-6 results from the cytokine analyses are presented in Table 6. 
The correlation between the untransformed data of these levels in the patient sample 
was not significant (r = 0.15, p = 0.39).  
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Table 6. IL-6 levels in plasma and CSF. 
 
Variable Plasma IL-6 CSF IL-6 
Suicide attempters n = 58 n = 39 
Levels (pg/mL), mean ± SEM 1.43 ± 0.17 1.0 ± 0.15 
Range 0.23-8.15 0.17-3.7 
Median, Quantile (0.1, 0.9) 1.12, 0.30, 3.0 0.67, 0.33, 2.27 
 
4.3.2 Plasma and CSF IL-6 levels and KSP personality factors 
The plasma IL-6 levels were significantly and positively correlated with the KSP 
personality factor extraversion (r = 0.48, p < 0.0001) (Fig. 5). In contrast, CSF IL-6 
levels were not significantly correlated with any personality factor (Table 7).  
 
 
Figure 5. Correlation between log plasma IL-6 and extraversion 
 
Table 7. Pearson’s r correlation between personality factors and plasma and CSF IL-6 
levels (log)  **p < 0.0001. 
 
Variable Plasma 
IL-6 
CSF IL-
6 
Neuroticism Psychoticism Extraversion Nonconformity 
Neuroticism -0.20 -0.09 1 0.45** 0.01 0.08 
Psychoticism -0.05 -0.04 0.45** 1 0.03 -0.11 
Extraversion 0.48** 0.25 0.01 0.03 
 
1 0.18 
Nonconformity 0.14 -0.10 0.08 -0.11 0.18 1 
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A standard linear regression model was used with the four KSP personality factors and 
age to predict plasma IL-6 levels. The regression model was significant: adjusted R-
square = 0.41, F = 8.8, DF = 5, p < 0.0001. Extraversion and age were independent and 
significant predictors of plasma IL-6 levels (Table 8).  
 
Table 8. Personality traits as predictors of plasma IL-6 in suicide attempters. R square = 
0.46 (F ratio = 8.8, DF = 5, p < 0.0001). 
 
Variable t ratio p value 
Extraversion 4.38 0.0001 
Psychoticism 0.23 0.82 
Neuroticism  -0.49 0.63 
Nonconformity 0.73 0.47 
Age 4.22 0.0001 
 
 
4.3.3 Plasma and CSF IL-6 levels and KSP extraversion subscales 
In the next step, a correlation analysis between the KSP subscales for extraversion 
(impulsiveness and monotony avoidance) and the plasma and CSF IL-6 levels was 
performed. Plasma IL-6 was significantly correlated with impulsiveness (r = 0.39, p < 
0.01; Fig. 6a) and monotony avoidance (r = 0.36, p < 0.01; Fig. 6b), whereas CSF IL-6 
was correlated with monotony avoidance (r = 0.35, p < 0.05; Fig. 6c). The correlation 
between CSF IL-6 and impulsiveness was not significant. 
 
Figure 6a. Correlation between log plasma IL-6 and impulsiveness. 
-2
-1
0
1
2
20 30 40 50 60 70
Impulsivity
Log plasma IL-6 Fitted values
Correlation between log plasma IL-6 and impulsivity
  36 
  
Figure 6b. Correlation between log plasma IL-6 and monotony avoidance.  
 
 
Figure 6c. Correlation between log CSF IL-6 and monotony avoidance.  
 
4.3.4 Plasma, CSF IL-6 and personality traits with regard to suicide attempt 
method 
Plasma and CSF IL-6 levels tended to be higher among suicide attempters who had 
used a violent method than among the nonviolent attempters (F = 3.51, p = 0.07; F = 
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2.4, p = 0.13, respectively). After adjusting for age and gender, the choice of a violent 
suicide attempt tended to be associated with higher plasma IL-6 levels (p = 0.051). 
 
Significant differences were not observed with regard to the extraversion scores for 
violent and nonviolent suicide attempters (p = 0.55).  
 
The regression model with plasma IL-6 as the dependent variable and age, choice of 
suicide attempt method, extraversion and the interaction between choice of method and 
extraversion did not reveal a significant interaction term (p = 0.13). When the non-
significant interaction term was removed from the model, it was significant (adjusted 
R-square = 0.45, F = 16.9, DF = 3, and p < 0.0001). Extraversion and age significantly 
predicted plasma IL-6 levels, whereas the choice of method tended to be significant (p 
= 0.07).  
 
4.3.5 Discussion 
The third study that is part of this thesis was designed to determine the potential effects 
of plausible endophenotypes determinable within our sample in relation to IL-6. The 
rationale for this was the finding that our results differed from those in previous studies 
with regards to IL-6 in relation to suicidal behavior, and also from findings in previous 
reports that IL-6 was also associated with depression in patients. Thus we could report 
that IL-6, in both plasma and the CSF, correlated with personality traits dominated by 
impulsivity or sensation-seeking in suicide attempters. We also saw that IL-6 tended to 
be higher, in both CSF and plasma, in suicide attempters who used a violent method, a 
finding consistent with a previous study conducted by Lindqvist and collaborators (63).  
 
We think our results are theoretically interesting, since they combine both earlier 
research on signs of aberrant inflammation and personality traits and research regarding 
features that may predispose to suicide risk, where the same traits from both research 
paths report on impulsivity as an important measure. So, adding to the complexity, we 
used endophenotypes determinable from the initial assessments and studied how these 
may influence IL-6. Based on this study, we could suggest the need to place an 
emphasis on personality measures, perhaps best done by using neurocognitive test 
batteries when undertaking biomarker studies. 
 
4.4 STUDY IV 
4.4.1 Sample characteristics 
The final sample consisted of 27 participants (12 men, mean age = 30.2, s.d. = 9.1, 
range = 22–53; 15 women, mean age = 27.5, s.d. = 6.7, range = 21-45). The 
characteristics of the study participants in the both exercise groups are presented in 
Table 9. There were no statistically significant differences between the exercise groups 
concerning gender distribution, age, or BMI (p values ranged between 0.45 and 0.86). 
 
All participants were screened negative for both a history of psychiatric disorder and 
any current psychiatric disorder. They were also screened negative for somatic 
morbidity, and routine clinical variables were all within normal reference values. 
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Participants were all nonsmokers, no self-reported history of substance-use disorder, 
and none were on any regular medication. Although not collected in all individuals, 
PHQ-9 was available for 15 participants at baseline and 17 participants post exercise 
(Table 9).  
 
Table 9. Descriptive statistics concerning the study population. 
 
Variable Total study group, 
n = 27 
Intensive exercise 
group, n = 14 
Moderate exercise 
group, n = 13 
Gender (n = 
male/female) 
12/15 6/8 6/7 
Age (years) mean ± 
SD, range 
28.7 ± 7.9, 21–53 28.1 ± 8.9, 22–53 29.2 ± 6.8, 21–45 
Age (years) mean ± 
SD, range (male) 
30.2 ± 9.1, 22–53 33.0 ± 12.3, 23–53 27.3 ± 3.7, 22–33 
Age (years) mean ± 
SD, range (female) 
27.5 ± 6.7, 21–45 24.5 ± 2.1, 22–28 30.9 ± 8.7, 21–45 
BMI (kg/m2) mean, 
range 
22.6 ± 2.6, 18.9-
29.6 
22.9 ± 2.7, 19.6–
29.6 
22.2 ± 2.5, 18.9–
28.0 
PHQ-9 at baseline,  
Mean ± SD, range 
1.9 ± 3.2, 0–11 
(n = 15) 
0.7 ± 1.2, 0–3 
(n = 6) 
0.4 ± 0.7, 0–2 
(n = 8) 
PHQ-9 post 
exercise,  
Mean ± SD, range 
1.2 ± 2.0, 0–7 
(n=17) 
2.8 ± 3.8, 0–11 
(n=9) 
2 ± 2.5, 0–7 
(n=9) 
 
 
4.4.2 Exercise habits and completion 
All participants included rated their habitual level of exercise based on the number of 
weekly sessions and the intensity of exercise, limited to the previous six months. In the 
intensive group, all participants were determined to have a high level of habitual 
exercise and, in the moderate group, six participants were determined to be sedentary, 
while the rest had a current moderate level of exercise. The habitual exercise habits and 
the number of completed exercise sessions are described in Table 10.    
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Table 10. Habitual exercise level at baseline and exercise sessions completed. 
 
Variable Intensive exercise 
group, n = 14 
Moderate exercise 
group, n = 13 
Habitual exercise level at baseline 
(Low-Moderate-High) 
High level, n = 14 Low level, n = 6 
Moderate level, n=7 
 
Exercises completed 
(Intensive group, 4 sessions intended, 
moderate group, 12 sessions intended) 
4 sessions 
completed, n = 14 
12 sessions 
completed, n = 9 
13 sessions 
completed, n = 3 
14 sessions 
completed, n = 1 
 
 
4.4.3 CSF immune markers and habitual exercise level 
The CSF levels of the assayed analytes that were above the detection limit are 
presented in Table 11. 
 
Baseline CSF IL-8 levels, pre-intervention, tended to be higher among the participants 
with a high habitual exercise level (p = 0.06, Kruskal-Wallis test).  
Baseline CSF IL-6 levels, pre-intervention, were not significantly different in the 
groups with different habitual exercise levels (p = 0.7, Kruskal-Wallis test). 
 
Table 11. IL-6 and IL-8 levels in CSF in total and across groups. 
 
Variable Total (n = 27) Intensive (n = 14) Moderate (n = 13) 
Pre CSF IL-6 
(pg/mL), mean ± 
SD 
1.99 ± 2.62 1.55 ± 0.95 2.46 ± 3.66 
Post CSF IL-6 
(pg/mL), mean ± 
SD 
2.46 ± 2.86 2.34 ± 1.87 2.59 ± 3.74 
Pre CSF IL-8 
(pg/mL), mean ± 
SD 
35.9 ± 12.7 40.2 ± 14.6 31 ± 8.74 
Post CSF IL-8 
(pg/mL), mean ± 
SD 
43.2 ± 13.6 46.7 ± 16.0 39.4 ± 9.7 
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4.4.4 CSF immune marker variability after exercise 
The pre- and post-variability for CSF IL-8 was significant for the group total (p = 
0.0002, Wilcoxon matched-pair signed-rank test); and for the testing across groups, 
intensive or moderate (p = 0.05, p = 0.005, Wilcoxon matched-pair signed-rank test) 
(Fig. 7). 
 
 
Figure 7. Box plot over CSF IL-8 (fg/mL) pre- and post-exercise. (***p < 0.0005). 
  
The pre- and post-variability for CSF IL-6 was not significant for the group total (p = 
0.13, Wilcoxon matched-pair signed-rank test); or for the testing across groups, 
intensive or moderate (p = 0.24, p = 0.24, Wilcoxon matched-pair signed-rank test). 
 
4.4.5 Serum immune markers and habitual exercise level 
The serum levels of the assayed analytes that were above the detection limit are 
presented in Table 12.  
 
Baseline serum IL-6, IL-8, and VEGF levels, pre-intervention were not significantly 
different according to the habitual exercise level (p values ranged between 0.44 and 
0.62, Kruskal-Wallis test). 
 
 
 
 
 
 
 
 
Pr
e C
SF
 IL
-8
 an
d 
Po
st 
CS
F 
IL-
8
10000
20000
30000
40000
50000
60000
70000
80000
90000
Pre_IL8
Post_IL8 *** 
  41 
Table 12. IL-6, IL-8 and VEGF levels in serum by total and across groups. 
 
Variable Total (n = 24) Intensive (n = 12) Moderate (n = 12) 
Pre IL-6 (pg/mL), 
mean ± SD 
0.21 ± 0.33 0.12 ± 0.16 0.30 ± 0.43 
Post IL-6 (pg/mL), 
mean ± SD 
0.42 ± 0.53 0.30 ± 0.31 0.55 ± 0.67 
Pre IL-8 (pg/mL), 
mean ± SD 
4.18 ± 3.12 4.02 ± 2.07 4.35 ± 4.00 
Post IL-8 (pg/mL), 
mean ± SD 
5.23 ± 3.13 4.42 ± 2.59 6.04 ± 3.51 
Pre VEGF 
(pg/mL), mean ± 
SD 
10.7 ± 11.2 8.6 ± 8.5 12.9 ± 13.4 
Post VEGF 
(pg/mL), mean ± 
SD 
11.8 ± 12.8 8.9 ± 8.9 14.8 ± 15.7 
 
4.4.6 Serum immune marker variability after exercise 
The pre- and post-variability of serum IL-6 was significant for the group total (p = 
0.003, Wilcoxon matched-pair signed-rank test) and for the intensive group (p = 0.01, 
Wilcoxon matched-pair signed-rank test) and tended to be significant in the moderate 
group (p = 0.09, Wilcoxon matched-pair signed-rank test) (Fig. 8).  
 
 
Figure 8. Box plot over serum IL-6 (fg/mL) pre- and post-exercise across groups (*p < 
0.05). 
 
Pr
e S
er
um
 IL
-6
 an
d 
Po
st 
Se
ru
m
 IL
-6
-500
0
500
1000
1500
2000
2500
Intensive Moderate
Exercise (Intensive-Moderate)
Serum_pre_IL6
Serum_post_IL6 * 
  42 
The pre- and post-variability of serum IL-8 was significant for the group total (p = 0.01, 
Wilcoxon matched-pair signed-rank test) and for the moderate group (p = 0.02, 
Wilcoxon matched-pair signed-rank test) and not significant for the intensive group (p 
= 0.42, Wilcoxon matched-pair signed-rank test) (Fig. 9).  
 
 
Figure 9. Box plot over serum IL-8 (fg/mL) pre- and post-exercise across groups. (*p < 
0.05). 
 
The pre- and post-variability of serum VEGF was not significant for the group total (p 
= 0.24, Wilcoxon matched-pair signed-rank test) or for the testing across groups, 
intensive or moderate (p = 0.73, p = 0.27, Wilcoxon matched-pair signed-rank test). 
 
4.4.7 Correlation between serum and CSF levels 
There was no significant correlation between serum and CSF levels of IL-6 and IL-8 in 
the baseline condition or after exercise (p values ranged between 0.37 and 0.99). 
 
4.4.8 Correlation between CSF levels of immune markers and mood ratings 
PHQ-9 ratings were not significantly changed after exercise (p = 0.15). At baseline, 
CSF IL-8 tended to be negatively correlated with the PHQ-9 score (Spearman’s ρ =      
–0.49, p = 0.06) and, after exercise, CSF IL-8 was significantly negatively correlated 
with the PHQ-9 score (Spearman’s ρ = –0.57, p = 0.02).  
 
4.4.9 Adverse events after lumbar puncture 
Two participants withdrew from further participation after baseline sampling because 
of post-puncture headache. All headaches reported were clinically typical of post-
puncture headache and were, in all cases, self-limited with spontaneous resolution after 
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a few days and did not hinder work or studies. No cases of severe complications 
occurred. 
 
4.4.10 Discussion 
The rationale for the fourth study was based on the fact that biomarker studies often 
rely on matched healthy comparison subjects to determine plausible differences of 
interest between the clinical subjects and healthy participants. It is acknowledged that 
many confounders are not readily adjusted for, but the effect on common immune 
markers of interest in psychiatric research relating to the habitual exercise level and of 
PE are not fully known and are rarely studied especially regarding the intrathecal 
compartment. 
 
We demonstrated that a physical activity intervention in healthy subjects results in 
alterations in the levels of certain cytokines in serum or CSF. A robust evidence base 
has confirmed the effect from PE on immune markers in the peripheral compartment; 
however, there is a paucity of studies that have addressed this issue in the intrathecal 
compartment. We found that, in paired samples from blood and CSF obtained from 
healthy participants, the degree of physiological variability in common immune 
markers can differ considerably and, for some cytokines, markedly as a result of 
physical exercise even at moderate intensity.  
 
The effect that physical activity exerts on psychiatric disorders, mostly stress-related 
and depressive disorders, is believed to be the result of a contribution to improved 
stress resilience and a return to stress homeostasis (125,126). A recent clinical study on 
patients with fibromyalgia, a condition characterized by chronic inflammation, 
supported this concept. The patients had increased levels of serum IL-8 at baseline, as 
well as an increased stress axis and cytokine activity compared to healthy subjects. This 
aberration was reversed to the level of that of the healthy subjects at baseline by a 
single session of moderate physical activity while the healthy subjects, in line with our 
study, had an increase in the same parameters (127).  
 
Further information emerging from this study was that many of the assayed analytes 
were below the detection limit. We believe, however, that this negative finding 
provides information that some cytokines are not heavily altered by physical exercise in 
healthy subjects and that they are generally low both at baseline and after exercise. 
 
We have in the previous study (Study II) reported that CSF IL-8 levels were lower in 
suicide attempters than in healthy controls. In this study, CSF IL-8 levels were highest 
among participants with a higher habitual exercise level. Furthermore, CSF IL-8 levels 
were negatively correlated with mood ratings. However, the mood ratings were very 
low in the participants, and whether or not this reflects a mechanistic role for CSF IL-8 
pertaining to mood merits further clarification.  
 
Thus, the main finding in this study was that most immune markers in the CSF were 
generally low in healthy subjects, which has implications for the sensitivity of 
detection, but with no relevant variability as a result of physical activity. CSF IL-8 was 
significantly elevated, however, as a result of physical activity across both exercise 
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groups; i.e., from a more acute exercise challenge as well as from more moderate 
exercise over time. We also found that CSF IL-8 tended to be higher at baseline in the 
participants who had a higher level of habitual physical exercise. Furthermore, CSF IL-
8 was negatively correlated with ratings of mood state among the participants both 
before and after exercise, suggesting that CSF IL-8 may be a state marker for mood and 
may be important for how exercise modulates mood. Serum IL-6 and IL-8 also display 
differential variability as a result of physical exercise, which is consistent with previous 
studies within this field. Collectively, this supports the notion that differences in the 
level of physical activity can affect biomarker levels in the intrathecal compartment and 
that efforts should be made to extend this type of analysis to a wider range of 
biomarkers. 
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5 CONCLUDING REMARKS AND FUTURE 
DIRECTIONS 
5.1 GENERAL DISCUSSION 
This thesis has focused on identifying biomarkers relevant for predicting or providing 
new insights into plausible mechanisms underlying the biology that drives suicidal 
behavior. In this context, the hope is that findings from this and other researchers’ work 
in this field may increase our understanding and in the future provide complementary 
tools for clinical assessment and new ways of targeting suicidal behavior with novel 
treatments that affects an aberrant immune activity.  
 
Research in neuroscience is a challenge because of the immense complexity of the 
human brain, and, today, psychiatric research has abandoned hope of finding single 
mechanisms that explain the pathophysiology. This thesis has also been produced 
during a period of time when the hope that neuroinflammation may be a relevant 
construct for use in psychiatric disorder pathophysiology has proved to be hard to 
replicate for individual biomarkers, and the findings reported have not been consistent. 
In that context, the second part of the thesis has relevance in that it fills a knowledge 
gap regarding the effects of physical exercise in the intrathecal compartment, and by so 
doing, further broadens our insight into how exercise may be a relevant confounder 
when conducting clinical studies.  
 
5.1.1 Dysregulated immune system 
The concept of chronic inflammation in this setting of studies is difficult to properly 
apprehend since there is no universal definition of such a state. There is, however, an 
abundance of studies that link increased morbidity and mortality with elevated levels of 
proinflammatory immune markers. A dysregulated or aberrant immune activity is 
perhaps a better description since inflammation, being in the classical sense, a reaction 
to pathogens or tissue damage, is not applicable in this context. The underlying causes 
of this dysregulation seem to converge on several underlying pathways, where an 
inherent genetic propensity for a strong immune response is one susceptibility factor, 
and depression may be the other side of the coin, bearing in mind the evolutionary 
advantage of a strong immune response for survival (128). 
 
Furthermore, immune activation is strongly associated with the stress response system, 
and early adverse stressors, or repeated severe or chronic stressors, have a direct impact 
on immune activity, and epigenetic modifications can alter the genome to a state of 
increased proinflammatory immune activity (129,130).  
 
5.1.1.1 Evidence for inflammation in the pathophysiology of psychiatric disorders 
 
There are many lines of evidence for a role of the immune system in such psychiatric 
disorders as depression and suicidal behavior. There are several reports where increased 
levels of cytokines, CRP and chemokines are evident. Furthermore, epidemiological 
findings have provided interesting associations even prospectively when it comes to IL-
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6 levels in childhood and a subsequent risk of depression (131). The same goes for 
evidence of prenatal or early childhood signs of inflammation or infection and the 
subsequent risk of mainly psychotic disorders (132,133). More convincing evidence 
comes from the important studies on IFN-α treatment and the risk of depression (134), 
as well as studies on lipopolysaccharide (LPS) injections with an evident increase in 
depressive symptoms in previously healthy subjects (135).  
 
Furthermore, in the context of suicidal behavior, evidence for an aberrant immune 
activation as a plausible pathomechanism comes from observational studies, where the 
previously known observation of an increase in suicidal behavior during different 
seasons such as spring, seemed to be mediated by peaks in aeroallergens (136), and also 
that the use of intranasal steroids, which reduces the amount of airway-induced 
cytokines, was negatively associated to suicidal behavior (137). There are more 
interesting observational associations reported, that the percentage of seropositivity for 
the common neurotropic parasite toxoplasma gondii, that knowingly induces an 
immune response, was significantly associated to a risk of suicidal behavior. An 
association that could be viewed upon, as corroborative for an underlying immune 
dysregulation, being involved in the unadaptive behavioral response involving suicidal 
behavior (136).   
 
5.1.1.2 Innate immune dysregulation 
 
Based on numerous studies, both preclinical and clinical, which argue that increased 
proinflammatory cytokines and chemokines have a role in the pathophysiology of 
depression, a role for a dysregulated activity mainly in the innate immune system is 
proposed. Innate immune mechanisms are the first line of defense against internal and 
external pathogens or stressors that challenge homeostasis or cell function. The 
interesting link between depression and other diseases linked to an aberrant immune 
activity, such as diabetes type 2 and obesity, corroborates this idea since these disorders 
are also suggested to be the result of a dysregulation in the innate immune system 
(138).  
 
Furthermore, even psychological stress has the ability to activate components of the 
innate immune system, and long-term stress or severe adverse events have the 
capability to alter these markers together with an alteration of the stress response 
system (139,140). Microglia within the brain can be activated and express the different 
aberrant cytokines and chemokines in depression and, as opposed to peripheral effects 
of cortisol, microglia expansion and cytokine expression is increased intrathecally by 
cortisol (140). Signs of microgliosis is also evident in suicidal behavior according to 
post mortem studies (140).  
 
5.1.2 Peripheral compartment vs. the intrathecal compartment 
It seems to be rational to assume that what goes on in the intrathecal compartment is a 
better measure of the immune activation signature pertaining to the brain and its 
surrounding structure, rather than the peripheral compartment. There are, however, 
obvious issues encountered in conducting CSF studies, since they involve a much more 
invasive procedure with known complications, such as post-spinal headache. From our 
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studies, and other CSF studies on suicidal behavior, it is evident that the peripheral 
compartment does not mirror the intrathecal compartment, and with no signs of 
correlation, indicating that these compartments are segregated in terms of immune 
marker expression, as was also the case in a previous exercise study, as well as results 
from our own exercise study reported in this thesis (63,141,142).  
 
This issue is also discussed in studies conducted on known neuroinflammatory 
disorders such as MS (143). The brain was previously regarded as an immune 
privileged organ; however, this view has been discarded for a long time and the brain is 
now referred to as being immune specialized (144). There is a constant surveillance by 
peripheral immune cells, but also from points of entry through the different barriers 
surrounding the brain, where not only the generally known blood-brain barrier (BBB), 
but also barriers between the blood and meninges and the choroid plexus are regions 
where cross-talk between immune cells takes place (144). An intriguing discovery in 
2015 also revealed that the brain is not only not as immune privileged as it was once 
thought to be, but that the brain also has a lymphatic drainage, which further opens up 
new ideas about how a neuroinflammation is instigated and may become chronic (145).  
 
5.1.3 A role for VEGF in attempted suicide 
There are quite a few studies, mainly preclinical, suggesting the putative role of VEGF 
in certain neuropsychiatric disorders, mainly depression. In chronic-stress paradigms in 
rodents VEGF expression in the hippocampus is down-regulated as well as its target 
receptor (146). There are also preclinical studies that have demonstrated VEGF down-
regulation in response to treatment with glucocorticoids (147,148). Exercise paradigms 
and, enriched environment paradigms have shown an increase in the expression of 
VEGF, with direct importance in, e.g., hippocampal neurogenesis (81,149). There are 
interesting links from animal studies that provide evidence that VEGF is a mediator 
involved in how antidepressants such as SRIs, PE, and electroconvulsive seizure 
(ECS), exerts theirs therapeutic effect (150–155).  
 
Clinical studies in humans have also provided corroborative evidence for VEGF to 
have a relevant role mainly regarding depression or stress-related disorders (73). 
However, due to the general complexity of clinical studies, the results are rather 
conflicting. One study reported that high levels of VEGF mRNA in peripheral 
leukocytes showed a significant correlation with the depression level (156). 
Furthermore Åsberg and collaborators reported that elevated plasma levels of VEGF 
were associated with prolonged sick-leave in women with a stress-related disorder, 
while another Japanese study reported decreased levels corresponding to stressful 
military training (157,158).  
 
Most clinical studies have reported elevated peripheral VEGF levels that correspond 
with psychiatric disorders (159–161). VEGF is a component of the innate immune 
response, and the main regulator for VEGF is hypoxia via the promoter hypoxia 
inducible factor 1 (HIF-1). Logically, the effect from external or internal stressors is an 
increase in VEGF as a reparative response. Recent reports have studied known 
polymorphisms for both VEGF and the VEGFR-2 (162–164) where polymorphisms 
associated to higher expression levels both regarding peripheral VEGF levels and 
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VEGFR-2 levels were associated to recurrent depression, and, in one study, by Viikki 
and collaborators to treatment resistant depression, but not to treatment response in the 
same study (162). Overall, these results, do not align in an intuitive way with the 
neurotrophic hypothesis of depression, where levels would rather be expected to be 
low. 
 
Contextualizing our studies with more recent reports have lifted the idea that low, and 
plausibly a hyporesponsive VEGF function may be a biomarker for treatment resistance 
in depression or more severe depressive states even characterized by risk of suicidal 
behavior (79,165). Studies I and II within this thesis present a key finding that VEGF 
levels are low both in plasma and in the CSF, and that low plasma levels were 
predictive of completed suicide (141,166). Studies and reports by Halaris and 
collaborators have discussed that elevated peripheral levels may serve as a biomarker 
for depression suggesting that elevated levels are a physiological response to stimulate 
neurogenesis, while, speculatively, low baseline levels could imply that the 
physiological ability to self-heal is impaired and therefore results in treatment 
resistance (79,167). A recent report presented evidence in line with this idea, where an 
optimal cut-off level for plasma VEGF could predict treatment response with 
antidepressant treatment in MDD subjects and where low baseline levels predicted non-
response (165). Clinical studies using antidepressant pharmacological therapies have 
failed to show associations between treatment response and concomitant increases in 
VEGF. However in treatment resistant depressive subjects electroconvulsive treatment 
(ECT) was associated to an increase in serum VEGF levels, and this was also 
associated to MADRS decline after intervention (168). Furthermore, a study, using 
sleep deprivation as intervention could report increases in VEGF levels and a 
correlation to improvement in mood in depressed subjects, while BDNF levels, 
remained unaltered (169). Taken together, these reports could indicate that VEGF 
response is to a larger degree dependent of non-pharmacological treatment options in 
humans as compared to regular pharmacological treatment options.  
 
While there are robust evidence from preclinical studies on neurogenesis being a 
relevant mechanism of action, a recent report proposes new interesting mechanisms 
regarding how VEGF may be efficacious in treatment and in which VEGFR-2, in an 
animal model was evidently involved in synaptic plasticity in the hippocampus, acting 
by, modulating the post synaptic responses by the N-methyl-D-aspartate type of 
glutamate receptors (GluNRs), thereby being of direct importance in modulating fear-
learning and memory consolidation.  
 
From the above perspective including studies presented after our initial clinical studies 
on the role of VEGF in suicidal behavior, we believe that the finding from Study I in 
which low levels of plasma VEGF were a significant predictor of completed suicide in 
a cohort of suicide attempters, aligns our results with the concept of treatment 
resistance if completed suicide is to be regarded as a more severe phenotype and 
indicator of treatment resistance. Furthermore, Study II, assessing CSF levels of VEGF, 
corroborates in a way, this idea since CSF levels were significantly lower in suicide 
attempters compared to healthy subjects. However, a relevant psychiatric comparison 
group such as MDD subjects without suicidal behavior would have further strengthened 
this finding.  
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A model for VEGF in treatment-resistant depression (TRD) and suicidal behavior is 
presented below (Fig. 10). 
 
Figure 10. A multifactorial model for VEGF down-regulation as a mediator and 
biomarker in the chain leading to treatment resistance and in some instances suicidal 
behavior, including risk for completed suicide. 
 
5.1.4 Physical exercise, immune modulation and therapeutics 
In the Introduction, the profound effects of PE are described in more detail. PE affects 
the immune system by mobilization of white blood cells and long-term effects on 
cytokines. The mechanisms for these alterations are thought to be achieved acutely via 
activation of the HPA axis, as well as the SNS via its effector molecules, as well as via 
signaling molecules derived directly from the skeletal musculature (myokines) (170).  
 
There is evidence from several epidemiological studies that a sedentary lifestyle is 
associated with an increased risk of depressive symptoms, and physical exercise is 
associated with a reduced risk of depressive symptoms in a dose-response fashion 
(171,172).  The differential effects in human brains of physical exercise are known 
from several clinical studies. Exercise has effects on cognitive domains, mainly 
visuospatial, thereby reducing cognitive decline in elderly populations, and imaging 
studies have also shown increased volumes in several brain regions, mainly the 
hippocampus, thereby providing indirect evidence that neuroplasticity occurs 
(125,173).  
 
There is evidence from clinical, as well as rodent, -studies that exercise modulates the 
monoaminergic system and has effects on NE, dopamine, and serotonin turnover (173). 
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Rodent studies also provide evidence that physical activity increases several 
neurotrophic growth factors, such as VEGF, BDNF, FGF-2, and insulin-like growth 
factor (IGF)-1; furthermore in humans, there is evidence for a transient peripheral 
increase of BDNF from PE (173,174) and even evidence for a central increase in 
BDNF (175). In our exercise study, we could not report any significant changes 
regarding VEGF in serum, and also VEGF assayed in the CSF was below the detection 
limit. This could be argued to be inconsistent with the Discussion above, however, at 
least from unpublished data from our lab-group VEGF levels generally are low in the 
intrathecal compartment and commonly falls close to or below the detection limit. 
 
Since the hippocampus is considered to be of importance in the pathophysiology of 
depression, as well as suicidal behavior (72,176,177), the connection with exercise-
induced neurogenesis in the hippocampus region, as well as reversing stress-induced 
depression from animal studies, provides support that physical exercise may be 
considered to be therapeutic and to act preventively through increased stress resilience 
(81,125,154,173).  
 
A rather new study from a research group at Karolinska Institutet also provide new 
interesting insights into how physical activity may prevent and increase stress-
resilience via induction of the muscle enzyme PGC-1α1. The PGC-1α1 enzymatic 
pathway increases the production of kynurenine aminotransferases (KATs) that 
catabolize kynurenine into kynurenic acid, a metabolite that is unable to cross the BBB. 
The study provides evidence from both transgenic mouse models and a clinical 
component that these effects actually occur. This opens up an interesting link in the 
connection between the before hand discussed cytokine aberration and a 
proinflammatory milieu as seen in chronic stress conditions. The induction of the 
kynurenine pathway previously discussed as an effect of increased inflammation and 
the role of PE as a possible means of preventing depression via increased resilience 
through the induction of a beneficial enzymatic pathway and, furthermore, as a way of 
treating depression via this mechanistic pathway (178).  
 
In this context, our Study IV also provides evidence that PE has a profound effect on 
immune markers, not only peripherally, but also in the intrathecal compartment. Our 
findings on CSF interleukin alterations are interesting, since, also for CSF IL-8, they 
seem to be correlated with ratings of mood. An interesting observation, in the light of 
the report showing that low CSF IL-8 levels were corresponding to anxiety in suicide 
attempters (123), and where PE could be an important tool in modulating an aberrant 
mood state, provided that our results indicate a plausible mechanism for how this may 
be achieved.  
 
Furthermore, on a more general level, in this type of research, there are discussions 
about whether patients with an aberrant immune activity are the ones that benefit the 
most from anti-inflammatory treatment and PE. Corroborative evidence in line with 
this idea is presented in the study on TNF-α inhibitor treatment for patients with 
treatment-resistant depression by Raison and collaborators, where CRP levels at 
baseline predicted response (179), and also an exercise study on patients with 
depression where baseline levels of TNF-α were a predictor of treatment response 
(180). 
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A schematic model is presented below (Fig. 11) describing possible mechanisms 
resulting from PE in both the peripheral compartment and the intrathecal compartment 
with effects on different modulators and pathways implied to be of importance in 
depression and suicidal behavior. 
 
Figure 11. A schematic model of beneficial effects of PE, i.e., improvement in stress 
resilience and return to homeostasis. 
 
5.1.5 Conclusion 
The studies reported in this thesis have introduced new data regarding potential 
biomarkers when assessing suicide risk and put forward ideas about how one can assess 
or understand inconsistencies between studies by aligning one of the included study’s 
design with the concept of endophenotypes, which is as a mean of deconstructing a 
broader clinical phenotype. Treatment resistance seems to be of utter importance, as 
reported by a Finnish longitudinal clinical study, with the interesting results indicating 
that the time spent in depression seemed to be the most important predictor of future 
suicide attempts (181) and, emphasizing the importance of having remission as a 
primary goal when treating patients suffering from MDD and adding support that 
suicide attempts are a more severe phenotype in MDD and an indicator of treatment 
resistance. Furthermore, assessing personality traits, or cognitive measures of 
impulsivity would seem to be important since studies from our group have provided 
data that personality domains have a further impact on immune markers even in a 
cohort of patients presenting with suicide attempts. We also stress that physical 
exercise has an impact on immune markers even in the intrathecal compartment, and 
these alterations could provide new ideas about how physical exercise may produce its 
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therapeutic effect, and that, in some settings, physical exercise could be a relevant 
confounder when conducting biomarker studies. 
 
5.1.5.1 Studies I-III 
From the first follow-up study (Study I), we report that low plasma levels of VEGF 
may be of predictive value regarding the risk of completed suicide in suicide attempters 
and, in that context, also a marker of treatment resistance. This must be replicated, 
however, in independent samples. 
 
From our second study (Study II), we report cross-sectional data indicating that low 
CSF levels of VEGF and IL-8 may constitute a biomarker for suicide risk as compared 
to healthy controls. 
 
In the third study (Study III), based on cross-sectional data, we also report that IL-6 
levels in plasma and in the CSF may be confounded by personality traits and the 
method of attempted suicide (violent/non-violent). We found a correlation mainly 
regarding IL-6 plasma levels and impulsiveness and sensation seeking traits, and to a 
lesser extent correlations between IL-6 CSF levels and sensation seeking traits. We 
believe that this merits further caution when assessing cytokines as biomarkers in 
suicide research, although today study designs often include neurocognitive testing. IL-
6 may also be associated with the choice of method, but this result did not reach 
statistical significance in our study. The study corroborates the idea of endophenotypes 
as relevant constructs to consider, and motivates the use, of dimensional phenotypic 
traits, conceptualized in the RDoC, when attempting and designing studies concerning 
suicidal behavior. 
 
5.1.5.2 Study IV 
The final study (Study IV) included in this thesis was organically derived to address 
potential confounding concerning the level of physical activity when comparing 
patients and healthy controls. This has not been extensively studied especially 
regarding the intrathecal compartment. Longitudinal paired data from both plasma and 
the CSF, as used in our study, is unique in this context, to our knowledge, and this 
experimental clinical study hopefully provides important information, not only in the 
field of psychoneuroimmunology, but also in the field of studies on other neurological 
inflammatory disorders. The results call for caution when attempting biomarker 
research in general, since the level of habitual physical activity, or any recent physical 
exertion, might have profound effects and this should therefore be either controlled for 
or ensured that conditions are equal with regard to physical activity. The results are also 
of interest when defining the plausible effect of immune markers as being therapeutic 
regarding neuropsychiatric disorders since we could also report that CSF IL-8 was 
correlated with mood, indicating a plausible role as a state marker. Furthermore, our 
paired sampling implies that the immune marker expression is segregated between the 
peripheral and the intrathecal compartment.  
 
5.1.5.3 Summary 
In summary, this thesis titled “Neuroinflammatory Biomarkers in Suicidal Behavior” 
has provided new information, mostly regarding VEGF as a potential biomarker of 
interest in suicidal behavior. Furthermore, the role of CSF IL-8 as a biomarker for both 
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suicidal behavior and mood is suggested by our results. We also provided new relevant 
input from screened healthy subjects on the effects of physical exercise and the habitual 
exercise level regarding immunological biomarkers, thereby reporting on the high 
degree of variability for some cytokines, also within the intrathecal compartment. 
 
5.1.6 Strengths 
5.1.6.1 Studies I-III 
The strength of the first part of the thesis was the thoroughly clinically assessed cohort 
of suicide attempters, with a strict protocol regarding biological sampling. Another was 
that we could include follow-up data on the cause of death. Paired sampling was 
provided from both plasma and CSF. The study sample was moderately large in this 
context. Moreover, the samples had never thawed prior to our analysis.  
 
5.1.6.2 Study IV 
The strengths regarding the second part of the thesis was the careful inclusion 
procedure which assured that the participants were completely healthy and without any 
history of psychiatric or medical problems. They were also assessed regarding 
concomitant immune activation using routine laboratory screening, and they were 
urged not to take any medication, even painkillers, during the study period. 
Furthermore, all participants were nonsmokers and there was no self-reported substance 
misuse. The paired sampling at both baseline and after exercise according to a strict 
protocol was unique in this context of studies. 
 
5.1.7 Limitations 
5.1.7.1 Studies I-III 
An important limitation regarding the first part of the thesis is the cross-sectional 
biological sampling and, regarding Studies II and III, the overall cross-sectional design 
that excludes the possibility of determining causality. The type of assay methodology is 
also an issue since reports have raised concerns about the reliability between the type of 
methodology and the producer of the assay technology, which may raise issues in the 
replication of study results (70). Another issue regarding the first part of the thesis is the 
long duration of time between sampling and assay, which has also raised concerns 
about the stability of immune markers, which may vary for each marker, even though 
they have never been thawed previously (184,185).  
 
Data on the subjects’ smoking habits were not assessed in a structured manner and 
hence were not adjusted for, but regarding peripheral VEGF levels there is one report 
stating that cigarette smoking did not affect VEGF levels in subjects with depression 
(186). We did not have data on socioeconomic status that also could be a relevant 
confounder in relation to cytokine levels. As for the healthy controls, these were all 
men and they were not age-matched. Patients not willing to undergo lumbar puncture 
or not willing to undergo any biological sampling at all could also affect the 
generalizability of the results in the first part of the thesis since these patients may have 
intrinsic differences in, e.g., personality traits or other phenotypical characteristics. 
Furthermore, the patient cohort could be determined to be a high-risk cohort, with a 
high degree of comorbidity and a high percentage of completed suicide attempts at 
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follow-up. This also raises issues concerning the generalizability of the findings since 
this group does not necessarily reflect the larger group of patients with issues regarding 
suicidal behavior. 
 
5.1.7.2 Study IV 
Limitations need to be pointed out regarding the second part of this study. The lack of 
supervision regarding the exercise protocol may raise concerns regarding protocol 
compliance. Differences in CSF levels are difficult to fully interpret and might also be a 
consequence of close-in-time physical exertion in a mere mechanistic way, e.g., 
extravasation of immune markers or changes in gradients, rather than a true increase in 
the expression of the immune markers that were assayed. The relevance of mood 
alterations and its correlation with one immune marker should be interpreted with 
caution since this reporting was incomplete, and the overall ratings in mood were low, 
as well as the alterations in mood rating after exercise being only subtly changed.  
 
5.2 FUTURE DIRECTIONS 
Psychiatric research is on the rise. There is an ongoing technological improvement 
within the field of genetics and collaborative efforts are key in increasing sample sizes 
as well as the generalizability of findings.  
 
Clinical research is complex and requires careful ethical consideration to make certain 
that, for individuals exposed to research, which may involve extra tribulations, all 
measures have been exhausted to ensure that the study design is well thought out. There 
are no animal models for suicidal behavior, which is limited to humans. However, there 
are known risk factors for which there are animal models, such as depressive-like 
behavior.  
 
Future studies should include imaging, genetic and epigenetic determination, 
neurocognitive domain testing together with the biological sampling, to investigate the 
biochemical milieu within the patient, also having in mind assessment of the stress 
hormone axis level of activity. Sampling needs to be performed at multiple time 
periods and ways to assess immune markers longitudinally must be found. One must 
also bear in mind for the study, the use of relevant comparison subjects, both 
psychiatric and healthy participants, with relevant matching based on different potential 
confounds. This kind of broad assessment is already being performed in other fields of 
psychiatric research, and with an increasing amount of optimism. Hopefully, these 
studies will also include the phenotypical characteristic that manifests itself through 
suicidal behavior.  
 
Furthermore, a few studies have been conducted on different types of anti-
inflammatory treatments for affective disorders, and the use of substances that 
modulate the glutamatergic system and the NMDA receptor is also an encouraging 
twist on how to move on from our current understanding of immune dysregulation in 
neuropsychiatric disorders. Even more new studies using physical activity, as a 
treatment should also attempt to determine what mechanisms are important, using 
results such as ours to understand what truly happens in humans after physical exercise. 
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We have the further ambition within our own group to use the collected data on 
personality and the biological samples from the exercise study to broaden our analysis 
regarding this cohort in order to explore other potential pathways that may be altered as 
a consequence of PE, as well as plausible connections to personality traits, with the aim 
of finding relevance regarding neuroinflammatory and psychiatric disorders. 
Furthermore, assaying BDNF in our subjects would be interesting in the light of 
previous research. 
 
 
  56 
6 ACKNOWLEDGMENTS 
First of all, I would like to humbly thank all the patients and other participants that so 
generously agreed to participate in these studies, without them this research would not 
have been achieved. 
 
I am very grateful to the Gadelius Foundation and the Thuring Foundation for financial 
support and to the Center for Psychiatric Research (CPF) for supporting psychiatric 
research and supporting this project. 
 
I wish to thank my main supervisor professor Jussi Jokinen for giving me the 
opportunity to take on this interesting research topic within the field of 
psychoneuroimmunology. Your deep knowledge in suicidology, patience and swift 
response to questions have been invaluable. I am forever grateful that you introduced 
me to and taught me the importance of science for me as a clinician.  
 
I also want to give my special and huge gratitude to my co-supervisor, Fredrik Piehl. It 
was your initiative to conduct the exercise study, and both your in-depth knowledge of 
neuroimmunology and clinical expertise make you a true role model when it comes to 
combining clinical work and research. You have also been utterly patient when 
teaching me about immunology and assay methodology. 
 
Thanks also to my other co-supervisors, Bo Runeson and Peter Nordström. Your 
knowledge in the field of suicidology and your input into this thesis have been of the 
utmost value.  
 
I am further grateful to my co-authors who also performed the biological assays in 
these studies: Fariborz Mobarrez, who gave invaluable assistance in the first study, and 
Shahin Aeinehband, for invaluable assistance with the first CSF study, interesting 
discussions regarding assay methodology, co-authoring the article, and also your great 
help in recruiting subjects for the fourth study!  
 
I would also express my gratitude to Mathias Granqvist, co-author and collaborator 
during the fourth exercise study. Your work and intellectual input have refined and 
made this study possible. 
 
I am also very happy to have been part of such a great team constituting our research 
group. Your input and discussions during journal clubs, as well as your companionship 
during a few congresses have given me many great memories. Thank you to; Peter 
Asellus, Marie Bendix, Philip Brenner, Andreas Chatzittofis, Tomas Moberg, Mia 
Rajalin, Cave Sinai and Jon Stefansson. 
 
My previous clinic, Psykiatri Nordväst, for support and giving me the opportunity to 
attend the National Research School in Psychiatry, as well as making it possible for me 
to combine clinical work and research. My current clinic, Psykiatri Sydväst, thanks to 
the Head of Operations, Nils Lindefors, and, Head of Section, Mats Adler, for 
  57 
supporting research by clinicians and giving me the opportunity to combine clinical 
work and research so as to finalize this thesis. 
 
Thanks to Yvonne Sedlenieks, Head Secretary at my previous work place, 
“Ångestenheten”, for allowing me to use up some office space doing some of this 
research and for always being helpful, with great enthusiasm and a smile! 
 
Also thanks to all my colleagues at both my old workplace, Ångestenheten, and my 
current workplaces, Mottagningen för tvångssyndrom and Centrum för Andrologi och 
Sexualmedicin. Special gratitude to my colleagues who gave both support and 
inspiration for research and for inviting me to clinical research in the workplace: Simon 
Cervenka, Diana Radu Djurfeldt, Christian Rück and Cecilia Svanborg.  
 
Thank you to my KI mentor Cecilia Dhejne for great and appreciated mentoring. You 
are truly a warm and generous friend and colleague, and I am always happy to get your 
input, inspiration and support.  
 
Thanks to Yasmina Molero for being a friend and also supporting me during this thesis 
with your knowledge and dark sense of humor! 
 
Thanks to my dear friend Kalle Lundgren for taking time to read through this thesis 
giving strong and important comments. You do have a sense for details! 
 
Thanks to Johan Ullman, my dear and long-time friend for great help in the exercise 
study. 
 
Thanks to Johan Reutfors former colleague and epidemiological researcher. You were 
the first one to inspire and recommend me to conduct research as a clinician. 
 
Thanks to all my friends and colleagues at the National Research School in Psychiatry. 
We had a great time, and I am happy we have stayed in touch after “graduation”.  
 
Further an immense thanks to all my dear and lovely friends for great support and love. 
None mentioned, none forgotten. 
 
Last, but not least, my wife Johanna and our two beautiful daughters. My daughters 
were welcomed to this world during this very time period; both of you are the apple of 
my eye, I love you! Johanna, there were moments of frustration and lack of inspiration, 
but you always stood there by my side; for this and so many other things, my love for 
you is infinite and eternal! 
 
 
 
  58 
7 REFERENCES 
1.  Bolton JM, Gunnell D, Turecki G. Suicide risk assessment and 
intervention in people with mental illness. BMJ. 2015 Nov 9;351:h4978.  
2.  Stefansson J, Nordström P, Runeson B, Åsberg M, Jokinen J. Combining 
the Suicide Intent Scale and the Karolinska Interpersonal Violence Scale in suicide risk 
assessments. BMC Psychiatry. 2015;15(1):226.  
3.  SBU. Instrument för bedömning av suicidrisk. En systematisk 
litteraturöversikt. [Internet]. Statens beredning för medicinsk och social utvärdering 
(SBU); 2015. Available from: 
http://www.sbu.se/upload/Publikationer/Content0/1/Instrument_bedomning_suicidrisk_
2015/Instrument_bedomning_suicidrisk_2015.pdf 
4.  O’Carroll PW, Berman AL, Maris RW, Moscicki EK, Tanney BL, 
Silverman MM. Beyond the Tower of Babel: A Nomenclature for Suicidology. Suicide 
Life Threat Behav. 1996;26(3):237–52.  
5.  Runeson B, Tidemalm D, Dahlin M, Lichtenstein P, Långström N. 
Method of attempted suicide as predictor of subsequent successful suicide: national 
long term cohort study. BMJ. 2010;341:c3222.  
6.  Träskman L, Asberg M, Bertilsson L, Sjöstrand L. Monoamine 
metabolites in CSF and suicidal behavior. Arch Gen Psychiatry. 1981 Jun;38(6):631–6.  
7.  WHO | Preventing suicide: A global imperative [Internet]. WHO. [cited 
2015 Sep 19]. Available from: http://www.who.int/mental_health/suicide-
prevention/world_report_2014/en/ 
8.  Jiang G-X, Hadlaczky G, Wasserman D. Självmord i Sverige Data: 1980-
2013 [Internet]. NASP Karolinska Institutet & Stockholms läns landsting; Available 
from: http://ki.se/nasp/statistikrapporter-0 
9.  Turecki G, Brent DA. Suicide and suicidal behaviour. Lancet Lond Engl. 
2015 Sep 15;  
10.  Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide 
mortality in mental disorders: a meta-review. World Psychiatry Off J World Psychiatr 
Assoc WPA. 2014 Jun;13(2):153–60.  
11.  Oquendo MA, Sullivan GM, Sudol K, Baca-Garcia E, Stanley BH, 
Sublette ME, et al. Toward a Biosignature for Suicide. Am J Psychiatry. 2014 Dec 
1;171(12):1259–77.  
12.  Mann JJ, Waternaux C, Haas GL, Malone KM. Toward a clinical model 
of suicidal behavior in psychiatric patients. Am J Psychiatry. 1999 Feb;156(2):181–9.  
13.  Turecki G. The molecular bases of the suicidal brain. Nat Rev Neurosci. 
2014 Dec;15(12):802–16.  
14.  Sullivan PF. The Psychiatric GWAS Consortium: Big Science Comes to 
Psychiatry. Neuron. 2010 Oct 21;68(2):182–6.  
15.  Sokolowski M, Wasserman J, Wasserman D. Polygenic associations of 
neurodevelopmental genes in suicide attempt. Mol Psychiatry. 2015 Dec 15;  
16.  Niculescu AB, Levey DF, Phalen PL, Le-Niculescu H, Dainton HD, Jain 
N, et al. Understanding and predicting suicidality using a combined genomic and 
clinical risk assessment approach. Mol Psychiatry. 2015 Nov;20(11):1266–85.  
17.  Kocerha J, Dwivedi Y, Brennand KJ. Noncoding RNAs and 
neurobehavioral mechanisms in psychiatric disease. Mol Psychiatry. 2015 
  59 
Jun;20(6):677–84.  
18.  Nicolaides NC, Kyratzi E, Lamprokostopoulou A, Chrousos GP, 
Charmandari E. Stress, the stress system and the role of glucocorticoids. 
Neuroimmunomodulation. 2015;22(1-2):6–19.  
19.  Elenkov IJ, Iezzoni DG, Daly A, Harris AG, Chrousos GP. Cytokine 
dysregulation, inflammation and well-being. Neuroimmunomodulation. 
2005;12(5):255–69.  
20.  Chandley MJ, Ordway GA. Noradrenergic Dysfunction in Depression 
and Suicide. 2012 [cited 2015 Dec 14]; Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK107205/ 
21.  Yehuda R, Halligan SL, Golier JA, Grossman R, Bierer LM. Effects of 
trauma exposure on the cortisol response to dexamethasone administration in PTSD 
and major depressive disorder. Psychoneuroendocrinology. 2004 Apr;29(3):389–404.  
22.  Jokinen J, Carlborg A, Martensson B, Forslund K, Nordstrom A-L, 
Nordstrom P. DST non-suppression predicts suicide after attempted suicide. Psychiatry 
Res. 2007 Apr 15;150(3):297–303.  
23.  Coryell W, Schlesser M. The dexamethasone suppression test and suicide 
prediction. Am J Psychiatry. 2001 May;158(5):748–53.  
24.  Mann JJ, Currier D, Stanley B, Oquendo MA, Amsel LV, Ellis SP. Can 
biological tests assist prediction of suicide in mood disorders? Int J 
Neuropsychopharmacol Off Sci J Coll Int Neuropsychopharmacol CINP. 2006 
Aug;9(4):465–74.  
25.  Yerevanian BI, Feusner JD, Koek RJ, Mintz J. The dexamethasone 
suppression test as a predictor of suicidal behavior in unipolar depression. J Affect 
Disord. 2004 Dec;83(2-3):103–8.  
26.  Lindqvist D, Isaksson A, Träskman-Bendz L, Brundin L. Salivary 
cortisol and suicidal behavior--a follow-up study. Psychoneuroendocrinology. 2008 
Sep;33(8):1061–8.  
27.  Lindqvist D, Träskman-Bendz L, Vang F. Suicidal intent and the HPA-
axis characteristics of suicide attempters with major depressive disorder and adjustment 
disorders. Arch Suicide Res Off J Int Acad Suicide Res. 2008;12(3):197–207.  
28.  Labonte B, Turecki G. The epigenetics of suicide: explaining the 
biological effects of early life environmental adversity. Arch Suicide Res. 
2010;14:291–310.  
29.  Jawahar MC, Murgatroyd C, Harrison EL, Baune BT. Epigenetic 
alterations following early postnatal stress: a review on novel aetiological mechanisms 
of common psychiatric disorders. Clin Epigenetics. 2015 Nov 14;7(1):122.  
30.  Asberg M, Träskman L, Thorén P. 5-HIAA in the cerebrospinal fluid. A 
biochemical suicide predictor? Arch Gen Psychiatry. 1976 Oct;33(10):1193–7.  
31.  Samuelsson M, Jokinen J, Nordström A-L, Nordström P. CSF 5-HIAA, 
suicide intent and hopelessness in the prediction of early suicide in male high-risk 
suicide attempters. Acta Psychiatr Scand. 2006 Jan 1;113(1):44–7.  
32.  Pandey GN, Dwivedi Y. Peripheral Biomarkers for Suicide. 2012 [cited 
2015 Oct 29]; Available from: http://www.ncbi.nlm.nih.gov/books/NBK107201/ 
33.  Bach H, Arango V. Neuroanatomy of Serotonergic Abnormalities in 
Suicide. In: Dwivedi Y, editor. The Neurobiological Basis of Suicide [Internet]. Boca 
Raton (FL): CRC Press; 2012 [cited 2015 Oct 12]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK107204/ 
  60 
34.  Klein DN, Kotov R, Bufferd SJ. Personality and depression: explanatory 
models and review of the evidence. Annu Rev Clin Psychol. 2011;7:269–95.  
35.  Goldstein BL, Klein DN. A Review of Selected Candidate 
Endophenotypes for Depression. Clin Psychol Rev. 2014 Jul;34(5):417–27.  
36.  Turecki G. Dissecting the suicide phenotype: the role of impulsive-
aggressive   behaviours. J Psychiatry Neurosci. 2005 Nov;30(6):398–408.  
37.  Mann JJ, Arango VA, Avenevoli S, Brent DA, Champagne FA, Clayton 
P. Candidate endophenotypes for genetic studies of suicidal behavior. Biol Psychiatry. 
2009;65:556–63.  
38.  Niv S, Tuvblad C, Raine A, Wang P, Baker LA. Heritability and 
longitudinal stability of impulsivity in adolescence. Behav Genet. 2012 
May;42(3):378–92.  
39.  Nordström P, Schalling D, Asberg M. Temperamental vulnerability in 
attempted suicide. Acta Psychiatr Scand. 1995 Aug;92(2):155–60.  
40.  McGirr A, Turecki G. The relationship of impulsive aggressiveness to 
suicidality and other depression-linked behaviors. Curr Psychiatry Rep. 2007 
Dec;9(6):460–6.  
41.  Doihara C, Kawanishi C, Yamada T, Sato R, Hasegawa H, Furuno T, et 
al. Trait aggression in suicide attempters: A pilot study. Psychiatry Clin Neurosci. 2008 
Jun;62(3):352–4.  
42.  Rujescu D, Giegling I. Intermediate Phenotypes in Suicidal Behavior 
Focus on Personality. 2012 [cited 2015 Dec 14]; Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK107202/ 
43.  Turiano NA, Mroczek DK, Moynihan J, Chapman BP. Big 5 personality 
traits and interleukin-6: evidence for “healthy Neuroticism” in a US population sample. 
Brain Behav Immun. 2013 Feb;28:83–9.  
44.  Chapman BP, van Wijngaarden E, Seplaki CL, Talbot N, Duberstein P, 
Moynihan J. Openness and conscientiousness predict 34-week patterns of Interleukin-6 
in older persons. Brain Behav Immun. 2011 May;25(4):667–73.  
45.  Sutin AR, Terracciano A, Deiana B, Naitza S, Ferrucci L, Uda M, et al. 
High neuroticism and low conscientiousness are associated with interleukin-6. Psychol 
Med. 2010 Sep;40(9):1485–93.  
46.  Sutin AR, Milaneschi Y, Cannas A, Ferrucci L, Uda M, Schlessinger D, 
et al. Impulsivity-related traits are associated with higher white blood cell counts. J 
Behav Med. 2011 Dec 22;  
47.  Ritchie SA, Connell JMC. The link between abdominal obesity, 
metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis NMCD. 
2007 May;17(4):319–26.  
48.  Henningsson S, Hakansson A, Westberg L, Landen M, Baghaei F, 
Rosmond R, et al. Association between interleukin-6 gene polymorphism and 
personality   traits in women. Nord J Psychiatry. 2004 Apr;58(2):97–97.  
49.  Chapman BP, Khan A, Harper M, Stockman D, Fiscella K, Walton J, et 
al. Gender, race/ethnicity, personality, and interleukin-6 in urban primary care patients. 
Brain Behav Immun. 2009 Jul;23(5):636–42.  
50.  Coccaro EF, Lee R, Coussons-Read M. Elevated Plasma Inflammatory 
Markers in Individuals With Intermittent Explosive Disorder and Correlation With 
Aggression in Humans. JAMA Psychiatry. 2013 Dec 18;  
51.  Suchankova P, Holm G, Träskman-Bendz L, Brundin L, Ekman A. The 
  61 
+1444C>T polymorphism in the CRP gene: a study on personality traits and suicidal 
behaviour. Psychiatr Genet. 2013 Apr;23(2):70–6.  
52.  Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. 
Research domain criteria (RDoC): toward a new classification framework for research 
on mental disorders. Am J Psychiatry. 2010 Jul;167(7):748–51.  
53.  Weinberger DR, Glick ID, Klein DF. Whither research domain criteria 
(rdoc)?: The good, the bad, and the ugly. JAMA Psychiatry. 2015 Nov 11;1161–2.  
54.  Yee CM, Javitt DC, Miller GA. Replacing dsm categorical analyses with 
dimensional analyses in psychiatry research: The research domain criteria initiative. 
JAMA Psychiatry. 2015 Nov 11;1159–60.  
55.  Kraemer H. REsearch domain criteria (rdoc) and the dsm—two 
methodological approaches to mental health diagnosis. JAMA Psychiatry. 2015 Nov 
11;1163–4.  
56.  Davis J, Maes M, Andreazza A, McGrath JJ, Tye SJ, Berk M. Towards a 
classification of biomarkers of neuropsychiatric disease: from encompass to compass. 
Mol Psychiatry. 2015 Feb;20(2):152–3.  
57.  Pine DS, Leibenluft E. Biomarkers With a Mechanistic Focus. JAMA 
Psychiatry. 2015 Jul;72(7):633–4.  
58.  Smith RS. The macrophage theory of depression. Med Hypotheses. 1991 
Aug;35(4):298–306.  
59.  Pallasch TJ, Wahl MJ. Focal infection: new age or ancient history? 
Endod Top. 2003 Sep 1;4(1):32–45.  
60.  Raison CL, Capuron L, Miller AH. Cytokines sing the blues: 
inflammation and the pathogenesis of depression. Trends Immunol. 2006 Jan;27(1):24–
31.  
61.  Leonard BE. Impact of inflammation on neurotransmitter changes in 
major depression: an insight into the action of antidepressants. Prog 
Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:261–7.  
62.  Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From 
inflammation to sickness and depression: when the immune system subjugates the 
brain. Nat Rev Neurosci. 2008 Jan;9(1):46–56.  
63.  Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, 
et al. Interleukin-6 Is Elevated in the Cerebrospinal Fluid of Suicide   Attempters and 
Related to Symptom Severity. Biol Psychiatry. 2009 Aug 1;66(3):287–92.  
64.  Kim Y-K, Lee S-W, Kim S-H, Shim S-H, Han S-W, Choi S-H, et al. 
Differences in cytokines between non-suicidal patients and suicidal   patients in major 
depression. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):356–61.  
65.  Janelidze S, Mattei D, Westrin Å, Träskman-Bendz L, Brundin L. 
Cytokine levels in the blood may distinguish suicide attempters from depressed 
patients. Brain Behav Immun. 2011 Feb;25(2):335–9.  
66.  Janelidze S, Ventorp F, Erhardt S, Hansson O, Minthon L, Flax J, et al. 
Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters. 
Psychoneuroendocrinology. 2013 Jun;38(6):853–62.  
67.  Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric 
adverse effects of interferon-alpha: recognition and management. CNS Drugs. 
2005;19(2):105–23.  
68.  Capuron L, Hauser P, Hinze-Selch D, Miller AH, Neveu PJ. Treatment of 
cytokine-induced depression. Brain Behav Immun. 2002 Oct;16(5):575–80.  
  62 
69.  Tonelli LH, Stiller J, Rujescu D, Giegling I, Schneider B, Maurer K, et al. 
Elevated cytokine expression in the orbitofrontal cortex of victims of   suicide. Acta 
Psychiatr Scand. 2008 Mar;117(3):198–206.  
70.  Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, et al. 
Immunological aspects in the neurobiology of suicide: Elevated   microglial density in 
schizophrenia and depression is associated with   suicide. J Psychiatr Res. 2008 
Jan;42(2):151–7.  
71.  Beumer W, Gibney SM, Drexhage RC, Pont-Lezica L, Doorduin J, Klein 
HC, et al. The immune theory of psychiatric diseases: a key role for activated microglia 
and circulating monocytes. J Leukoc Biol [Internet]. 2012 Aug 8 [cited 2012 Aug 13]; 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/22875882 
72.  Duman RS, Monteggia LM. A neurotrophic model for stress-related 
mood disorders. Biol Psychiatry. 2006 Jun 15;59(12):1116–27.  
73.  Fournier NM, Duman RS. Role of vascular endothelial growth factor in 
adult hippocampal neurogenesis: implications for the pathophysiology and treatment of 
depression. Behav Brain Res. 2012 Feb 14;227(2):440–9.  
74.  Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets 
neuropsychopharmacology: translational implications of the impact of inflammation on 
behavior. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2012 
Jan;37(1):137–62.  
75.  Björkholm C, Monteggia LM. BDNF - a key transducer of antidepressant 
effects. Neuropharmacology. 2015 Nov 11;102:72–9.  
76.  Pandey GN, Ren X, Rizavi HS, Conley RR, Roberts RC, Dwivedi Y. 
Brain-derived neurotrophic factor and tyrosine kinase B receptor signalling in post-
mortem brain of teenage suicide victims. Int J Neuropsychopharmacol Off Sci J Coll 
Int Neuropsychopharmacol CINP. 2008 Dec;11(8):1047–61.  
77.  Paska AV, Zupanc T, Pregelj P. The role of brain-derived neurotrophic 
factor in the pathophysiology of suicidal behavior. Psychiatr Danub. 2013 Sep;25 Suppl 
2:S341–4.  
78.  Eyre H, Baune BT. Neuroplastic changes in depression: A role for the 
immune system. Psychoneuroendocrinology [Internet]. [cited 2012 Apr 24]; Available 
from: http://www.sciencedirect.com/science/article/pii/S0306453012001242 
79.  Clark-Raymond A, Halaris A. VEGF and depression: a comprehensive 
assessment of clinical data. J Psychiatr Res. 2013 Aug;47(8):1080–7.  
80.  Griffin ÉW, Mullally S, Foley C, Warmington SA, O’Mara SM, Kelly 
AM. Aerobic exercise improves hippocampal function and increases BDNF in the 
serum of young adult males. Physiol Behav. 2011 Oct 24;104(5):934–41.  
81.  Fabel K, Fabel K, Tam B, Kaufer D, Baiker A, Simmons N, et al. VEGF 
is necessary for exercise-induced adult hippocampal neurogenesis. Eur J Neurosci. 
2003 Nov;18(10):2803–12.  
82.  Swain DP, American College of Sports Medicine, American College of 
Sports Medicine, editors. ACSM’s resource manual for Guidelines for exercise testing 
and prescription. 7th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & 
Wilkins; 2014. 862 p.  
83.  Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo 
MA. The anti-inflammatory effects of exercise: mechanisms and implications for the 
prevention and treatment of disease. Nat Rev Immunol. 2011 Sep;11(9):607–15.  
84.  Walsh NP, Gleeson M, Shephard RJ, Gleeson M, Woods JA, Bishop NC, 
  63 
et al. Position statement. Part one: Immune function and exercise. Exerc Immunol Rev. 
2011;17:6–63.  
85.  Walsh NP, Gleeson M, Pyne DB, Nieman DC, Dhabhar FS, Shephard RJ, 
et al. Position statement. Part two: Maintaining immune health. Exerc Immunol Rev. 
2011;17:64–103.  
86.  Black C, Miller BJ. Meta-Analysis of Cytokines and Chemokines in 
Suicidality: Distinguishing Suicidal Versus Nonsuicidal Patients. Biol Psychiatry. 2015 
Jul 1;78(1):28–37.  
87.  Ganança L, Oquendo MA, Tyrka AR, Cisneros-Trujillo S, Mann JJ, 
Sublette ME. The role of cytokines in the pathophysiology of suicidal behavior. 
Psychoneuroendocrinology. 2016 Jan 1;63:296–310.  
88.  Miná V a. L, Lacerda-Pinheiro SF, Maia LC, Pinheiro RFF, Meireles CB, 
de Souza SIR, et al. The influence of inflammatory cytokines in physiopathology of 
suicidal behavior. J Affect Disord. 2014 Oct 12;172C:219–30.  
89.  Ducasse D, Olié E, Guillaume S, Artéro S, Courtet P. A meta-analysis of 
cytokines in suicidal behavior. Brain Behav Immun. 2015 May;46:203–11.  
90.  Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, 
Samuelsson M, et al. Connecting inflammation with glutamate agonism in suicidality. 
Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2013 
Apr;38(5):743–52.  
91.  Bradley KAL, Case JAC, Khan O, Ricart T, Hanna A, Alonso CM, et al. 
The role of the kynurenine pathway in suicidality in adolescent major depressive 
disorder. Psychiatry Res. 2015 Jun 30;227(2-3):206–12.  
92.  Schwarcz R, Bruno JP, Muchowski PJ, Wu H-Q. Kynurenines in the 
Mammalian Brain: When Physiology Meets Pathology. Nat Rev Neurosci. 2012 
Jul;13(7):465–77.  
93.  Dwivedi Y. Brain-derived neurotrophic factor and suicide pathogenesis. 
Ann Med. 2010 Mar;42(2):87–96.  
94.  Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P. Role 
and therapeutic potential of VEGF in the nervous system. Physiol Rev. 2009 
Apr;89(2):607–48.  
95.  Vogel G. Developmental biology - The unexpected brains behind blood 
vessel growth. Science. 2005 Feb 4;307(5710):665 – +.  
96.  Blumberg HP, Wang F, Chepenik LG, Kalmar JH, Edmiston E, Duman 
RS, et al. Influence of Vascular Endothelial Growth Factor Variation on Human   
Hippocampus Morphology. Biol Psychiatry. 2008 Nov 15;64(10):901–3.  
97.  Rosenstein JM, Krum JM, Ruhrberg C. VEGF in the nervous system. 
Organogenesis. 2010 Jun;6(2):107–14.  
98.  Warner-Schmidt JL, Duman RS. Hippocampal neurogenesis: opposing 
effects of stress and antidepressant treatment. Hippocampus. 2006;16(3):239–49.  
99.  Spitzer RL, Williams JB, Gibbon M, First MB. Structured Clinical 
Interview for DSM-III-R. Washington, D.C: American Psychiatric Press, Inc.; 1990.  
100.  Montgomery SA, Asberg M. A new depression scale designed to be 
sensitive to change. Br J Psychiatry J Ment Sci. 1979 Apr;134:382–9.  
101.  Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, 
et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development 
and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-
10. J Clin Psychiatry. 1998;59 Suppl 20:22–33;quiz 34–57.  
  64 
102.  Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief 
depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606–13.  
103.  Beck A, Schuyler D, Herman I. Development of suicidal intent scales. In: 
The prediction of suicide. Philadelphia, PA: Charles Press; p. 45–56.  
104.  Mieczkowski T, Sweeney J, Haas G, Junker B, Brown R, Mann J. Factor 
Composition Of The Suicide Intent Scale. Suicide Life Threat Behav. 1993 
SPR;23(1):37–45.  
105.  Schalling D, Edman G. The Karolinska Scales of Personality (KSP). An 
Inventory for Assessing Temperament Dimensions Associated with Vulnerability for 
Psychosocial Deviance. The Department of Psychiatry, The Karolinska Institute, 
Stockholm; 1993.  
106.  Gustavsson JP, Weinryb RM, Goransson S, Pedersen NL, Asberg M. 
Stability and predictive ability of personality traits across 9 years. Personal Individ 
Differ. 1997 Jun;22(6):783–91.  
107.  Ortet G, Ibanez MI, Llerena A, Torrubia R. The underlying traits of the 
Karolinska Scales of Personality (KSP). Eur J Psychol Assess. 2002;18(2):139–48.  
108.  Hirvikoski T, Jokinen J. Personality traits in attempted and completed 
suicide. Eur Psychiatry. 2012 Oct;27(7):536–41.  
109.  Gustavsson JP, Bergman H, Edman G, Ekselius L, von Knorring L, 
Linder J. Swedish universities Scales of Personality (SSP): construction, internal 
consistency and normative data. Acta Psychiatr Scand. 2000 Sep;102(3):217–25.  
110.  Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports 
Exerc. 1982;14(5):377–81.  
111.  Chen MJ, Fan XT, Moe ST. Criterion-related validity of the Borg ratings 
of perceived exertion scale in healthy individuals: a meta-analysis. J Sports Sci. 2002 
Nov;20(11):873–99.  
112.  Ciolac EG, Mantuani SS, Neiva CM, Verardi C, Pessôa-Filho DM, 
Pimenta L. Rating of perceived exertion as a tool for prescribing and self regulating 
interval training: a pilot study. Biol Sport. 2015 Jun;32(2):103–8.  
113.  Fitzgerald SP, Lamont JV, McConnell RI, Benchikh EO. Development of 
a high-throughput automated analyzer using biochip array technology. Clin Chem. 
2005 Jul;51(7):1165–76.  
114.  Albitar M. Monoclonal Antibodies: Methods and Protocols. Humana 
Press, Totowa, NJ; 2007.  
115.  Tabachnick BG. Using Multivariate Statistics. 6th ed. Boston, Mass. ; 
London: Pearson Education; 2013. 983 p.  
116.  Nassberger L, Träskman-Bendz L. Increased Soluble Interleukin-2 
Receptor Concentrations in Suicide Attempters. Acta Psychiatr Scand. 1993 
Jul;88(1):48–52.  
117.  Smith K. The Interleukin-2 Receptor. Adv Immunol. 1988;42:165–79.  
118.  Smith KA, Popmihajlov Z. The quantal theory of immunity and the 
interleukin-2-dependent negative   feedback regulation of the immune response. 
Immunol Rev. 2008 Aug;224:124–40.  
119.  Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical 
psychiatry. Am J Psychiatry. 2000 May;157(5):683–94.  
120.  Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular 
endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 
in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) 
  65 
complex. J Biol Chem. 2009 Mar 6;284(10):6038–42.  
121.  Lehto SM, Niskanen L, Herzig K-H, Tolmunen T, Huotari A, Viinamäki 
H, et al. Serum chemokine levels in major depressive disorder. 
Psychoneuroendocrinology. 2010 Feb;35(2):226–32.  
122.  Uher T, Bob P. Cerebrospinal fluid IL-8 levels reflect symptoms of 
alexithymia in patients with non-inflammatory neurological disorders. 
Psychoneuroendocrinology. 2011 Sep;36(8):1148–53.  
123.  Janelidze S, Suchankova P, Ekman A, Erhardt S, Sellgren C, Samuelsson 
M, et al. Low IL-8 is associated with anxiety in suicidal patients: genetic variation and 
decreased protein levels. Acta Psychiatr Scand. 2015 Apr;131(4):269–78.  
124.  Pfeiffer PN, Ganoczy D, Ilgen M, Zivin K, Valenstein M. Comorbid 
anxiety as a suicide risk factor among depressed veterans. Depress Anxiety. 
2009;26(8):752–7.  
125.  Eyre H, Baune BT. Neuroimmunological effects of physical exercise in 
depression. Brain Behav Immun. 2012 Feb;26(2):251–66.  
126.  Petersen AMW, Pedersen BK. The anti-inflammatory effect of exercise. J 
Appl Physiol Bethesda Md 1985. 2005 Apr;98(4):1154–62.  
127.  Bote ME, Garcia JJ, Hinchado MD, Ortega E. Fibromyalgia: Anti-
Inflammatory and Stress Responses after Acute Moderate Exercise. PLoS ONE 
[Internet]. 2013 Sep 4 [cited 2016 Jan 9];8(9). Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3762808/ 
128.  Raison CL, Miller AH. The evolutionary significance of depression in 
Pathogen Host Defense (PATHOS-D). Mol Psychiatry [Internet]. 2012 Jan 31 [cited 
2012 Oct 30]; Available from: 
http://www.nature.com/mp/journal/vaop/ncurrent/full/mp20122a.html 
129.  Krukowski K, Eddy J, Kosik KL, Konley T, Janusek LW, Mathews HL. 
Glucocorticoid Dysregulation of Natural Killer Cell Function through Epigenetic 
Modification. Brain Behav Immun. 2011 Feb;25(2):239–49.  
130.  Eddy JL, Krukowski K, Janusek L, Mathews HL. Glucocorticoids 
regulate natural killer cell function epigenetically. Cell Immunol. 2014 Jul;290(1):120–
30.  
131.  Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association 
of serum interleukin 6 and C-reactive protein in childhood with depression and 
psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry. 
2014 Oct;71(10):1121–8.  
132.  Brown AS, Hooton J, Schaefer CA, Zhang H, Petkova E, Babulas V, et 
al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. 
Am J Psychiatry. 2004 May;161(5):889–95.  
133.  Dalman C, Allebeck P, Gunnell D, Harrison G, Kristensson K, Lewis G, 
et al. Infections in the CNS during childhood and the risk of subsequent psychotic 
illness: a cohort study of more than one million Swedish subjects. Am J Psychiatry. 
2008 Jan;165(1):59–65.  
134.  Capuron L, Dantzer R, Miller AH. [Neuro-immune interactions in 
psychopathology with the example of interferon-alpha-induced depression]. J Société 
Biol. 2003;197(2):151–6.  
135.  Brundin L, Erhardt S, Bryleva EY, Achtyes ED, Postolache TT. The role 
of inflammation in suicidal behaviour. Acta Psychiatr Scand. 2015 Sep;132(3):192–
203.  
  66 
136.  Okusaga O, Postolache TT. Toxoplasma gondii, the Immune System, and 
Suicidal Behavior. In: Dwivedi Y, editor. The Neurobiological Basis of Suicide 
[Internet]. Boca Raton (FL): CRC Press; 2012 [cited 2013 Sep 16]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK107197/ 
137.  Woo J-M, Gibbons RD, Qin P, Komarow H, Kim JB, Rogers CA, et al. 
Suicide and prescription rates of intranasal corticosteroids and nonsedating 
antihistamines for allergic rhinitis: an ecological study. J Clin Psychiatry. 2011 
Oct;72(10):1423–8.  
138.  Moulton CD, Pickup JC, Ismail K. The link between depression and 
diabetes: the search for shared mechanisms. Lancet Diabetes Endocrinol. 2015 
Jun;3(6):461–71.  
139.  Haapakoski R, Ebmeier KP, Alenius H, Kivimäki M. Innate and adaptive 
immunity in the development of depression: An update on current knowledge and 
technological advances. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Nov 
26;66:63–72.  
140.  Yirmiya R, Rimmerman N, Reshef R. Depression as a microglial disease. 
Trends Neurosci. 2015 Oct;38(10):637–58.  
141.  Isung J, Aeinehband S, Mobarrez F, Mårtensson B, Nordström P, Asberg 
M, et al. Low vascular endothelial growth factor and interleukin-8 in cerebrospinal 
fluid of suicide attempters. Transl Psychiatry. 2012;2:e196.  
142.  Steensberg A, Dalsgaard MK, Secher NH, Pedersen BK. Cerebrospinal 
fluid IL-6, HSP72, and TNF-alpha in exercising humans. Brain Behav Immun. 2006 
Nov;20(6):585–9.  
143.  Han S, Lin YC, Wu T, Salgado AD, Mexhitaj I, Wuest SC, et al. 
Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with 
neuroimmunological diseases. J Immunol Baltim Md 1950. 2014 Mar 15;192(6):2551–
63.  
144.  Michel L, Touil H, Pikor NB, Gommerman JL, Prat A, Bar-Or A. B Cells 
in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to 
CNS-Compartmentalized Inflammation. Front Immunol [Internet]. 2015 Dec 24 [cited 
2016 Jan 20];6. Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689808/ 
145.  Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. 
Structural and functional features of central nervous system lymphatics. Nature. 2015 
Jul 16;523(7560):337–41.  
146.  Heine VM, Zareno J, Maslam S, Joels M, Lucassen PJ. Chronic stress in 
the adult dentate gyrus reduces cell proliferation   near the vasculature and VEGF and 
Flk-1 protein expression. Eur J Neurosci. 2005 Mar;21(5):1304–14.  
147.  Koedam JA, Smink JJ, van Buul-Offers SC. Glucocorticoids inhibit 
vascular endothelial growth factor expression in   growth plate chondrocytes. Mol Cell 
Endocrinol. 2002 Nov 29;197(1-2):35–44.  
148.  Greenberger S, Boscolo E, Adini I, Mulliken JB, Bischoff J. 
Corticosteroid Suppression of VEGF-A in Infantile Hemangioma-Derived   Stem Cells. 
N Engl J Med. 2010 Mar 18;362(11):1005–13.  
149.  Warner-Schmidt JL, Duman RS. VEGF as a potential target for 
therapeutic intervention in depression. Curr Opin Pharmacol. 2008 Feb;8(1):14–9.  
150.  Segi-Nishida E, Warner-Schmidt JL, Duman RS. Electroconvulsive 
seizure and VEGF increase the proliferation of neural   stem-like cells in rat 
  67 
hippocampus. Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11352–7.  
151.  Greene J, Banasr M, Lee B, Warner-Schmidt J, Duman RS. Vascular 
Endothelial Growth Factor Signaling is Required for the   Behavioral Actions of 
Antidepressant Treatment: Pharmacological and   Cellular Characterization. 
Neuropsychopharmacology. 2009 Oct;34(11):2459–68.  
152.  Sun R, Li N, Li T. VEGF regulates antidepressant effects of lamotrigine. 
Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol [Internet]. 2011 Oct 25 
[cited 2012 Mar 10]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/22033393 
153.  Warner-Schmidt JL, Duman RS. VEGF is an essential mediator of the 
neurogenic and behavioral actions   of antidepressants. Proc Natl Acad Sci U S A. 2007 
Mar 13;104(11):4647–52.  
154.  Kiuchi T, Lee H, Mikami T. Regular exercise cures depression-like 
behavior via VEGF-Flk-1 signaling in chronically stressed mice. Neuroscience 
[Internet]. 2012 Jan 20 [cited 2012 Mar 10]; Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/22306286 
155.  Elfving B, Wegener G. Electroconvulsive seizures stimulate the vegf 
pathway via mTORC1. Synap N Y N. 2012 Apr;66(4):340–5.  
156.  Iga J, Ueno S, Yamauchi K, Numata S, Tayoshi-Shibuya S, Kinouchi S, 
et al. Gene expression and association analysis of vascular endothelial growth   factor 
in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 
13;31(3):658–63.  
157.  Asberg M, Nygren A, Leopardi R, Rylander G, Peterson U, Wilczek L, et 
al. Novel Biochemical Markers of Psychosocial Stress in Women. Plos One. 2009 Jan 
30;4(1).  
158.  Suzuki G, Tokuno S, Nibuya M, Ishida T, Yamamoto T, Mukai Y, et al. 
Decreased Plasma Brain-Derived Neurotrophic Factor and Vascular Endothelial 
Growth Factor Concentrations during Military Training. PloS One. 2014;9(2):e89455.  
159.  Ventriglia M, Zanardini R, Pedrini L, Placentino A, Nielsen MG, 
Gennarelli M, et al. VEGF serum levels in depressed patients during SSRI 
antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Feb 
1;33(1):146–9.  
160.  Takebayashi M, Hashimoto R, Hisaoka K, Tsuchioka M, Kunugi H. 
Plasma levels of vascular endothelial growth factor and fibroblast   growth factor 2 in 
patients with major depressive disorders. J Neural Transm. 2010 Sep;117(9):1119–22.  
161.  Kahl KG, Bens S, Ziegler K, Rudolf S, Kordon A, Dibbelt L, et al. 
Angiogenic factors in patients with current major depressive disorder   comorbid with 
borderline personality disorder. Psychoneuroendocrinology. 2009 Apr;34(3):353–7.  
162.  Viikki M, Anttila S, Kampman O, Illi A, Huuhka M, Setala-Soikkeli E, et 
al. Vascular endothelial growth factor (VEGF) polymorphism is associated   with 
treatment resistant depression. Neurosci Lett. 2010 Jun 25;477(3):105–8.  
163.  Gałecki P, Gałecka E, Maes M, Orzechowska A, Berent D, Talarowska 
M, et al. Vascular endothelial growth factor gene (VEGFA) polymorphisms may serve 
as prognostic factors for recurrent depressive disorder development. Prog 
Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:117–24.  
164.  Gałecki P, Orzechowska A, Berent D, Talarowska M, Bobińska K, 
Gałecka E, et al. Vascular endothelial growth factor receptor 2 gene (KDR) 
polymorphisms and expression levels in depressive disorder. J Affect Disord. 2013 
May;147(1-3):144–9.  
  68 
165.  Clark-Raymond A, Meresh E, Hoppensteadt D, Fareed J, Sinacore J, 
Garlenski B, et al. Vascular endothelial growth factor: Potential predictor of treatment 
response in major depression. World J Biol Psychiatry Off J World Fed Soc Biol 
Psychiatry. 2016 Jan 4;1–11.  
166.  Isung J, Mobarrez F, Nordström P, Asberg M, Jokinen J. Low plasma 
vascular endothelial growth factor (VEGF) associated with completed suicide. World J 
Biol Psychiatry Off J World Fed Soc Biol Psychiatry. 2012 Sep;13(6):468–73.  
167.  Clark-Raymond A, Meresh E, Hoppensteadt D, Fareed J, Sinacore J, 
Halaris A. Vascular Endothelial Growth Factor: a potential diagnostic biomarker for 
major depression. J Psychiatr Res. 2014 Dec;59:22–7.  
168.  Minelli A, Zanardini R, Abate M, Bortolomasi M, Gennarelli M, 
Bocchio-Chiavetto L. Vascular Endothelial Growth Factor (VEGF) serum 
concentration during   electroconvulsive therapy (ECT) in treatment resistant depressed   
patients. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jul 1;35(5):1322–5.  
169.  Ibrahim L, Duncan W, Luckenbaugh DA, Yuan P, Machado-Vieira R, 
Zarate CA. Rapid antidepressant changes with sleep deprivation in major depressive   
disorder are associated with changes in vascular endothelial growth   factor (VEGF): A 
pilot study. Brain Res Bull. 2011 Aug 10;86(1-2):129–33.  
170.  Simpson RJ, Kunz H, Agha N, Graff R. Exercise and the Regulation of 
Immune Functions. Prog Mol Biol Transl Sci. 2015;135:355–80.  
171.  Pinto Pereira SM, Geoffroy M-C, Power C. Depressive symptoms and 
physical activity during 3 decades in adult life: bidirectional associations in a 
prospective cohort study. JAMA Psychiatry. 2014 Dec 1;71(12):1373–80.  
172.  Camacho TC, Roberts RE, Lazarus NB, Kaplan GA, Cohen RD. Physical 
activity and depression: evidence from the Alameda County Study. Am J Epidemiol. 
1991 Jul 15;134(2):220–31.  
173.  Hamilton GF, Rhodes JS. Exercise Regulation of Cognitive Function and 
Neuroplasticity in the Healthy and Diseased Brain. Prog Mol Biol Transl Sci. 
2015;135:381–406.  
174.  Knaepen K, Goekint M, Heyman EM, Meeusen R. Neuroplasticity - 
exercise-induced response of peripheral brain-derived neurotrophic factor: a systematic 
review of experimental studies in human subjects. Sports Med Auckl NZ. 2010 Sep 
1;40(9):765–801.  
175.  Rasmussen P, Brassard P, Adser H, Pedersen MV, Leick L, Hart E, et al. 
Evidence for a release of brain-derived neurotrophic factor from the brain during 
exercise. Exp Physiol. 2009 Oct 1;94(10):1062–9.  
176.  Yan H-C, Cao X, Gao T-M, Zhu X-H. Promoting adult hippocampal 
neurogenesis: a novel strategy for antidepressant drug screening. Curr Med Chem. 
2011;18(28):4359–67.  
177.  Dwivedi Y. Brain-Derived Neurotrophic Factor in Suicide 
Pathophysiology. 2012 [cited 2015 Nov 29]; Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK107216/ 
178.  Agudelo LZ, Femenía T, Orhan F, Porsmyr-Palmertz M, Goiny M, 
Martinez-Redondo V, et al. Skeletal muscle PGC-1α1 modulates kynurenine 
metabolism and mediates resilience to stress-induced depression. Cell. 2014 Sep 
25;159(1):33–45.  
179.  Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake 
DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist 
  69 
infliximab for treatment-resistant depression: the role of baseline inflammatory 
biomarkers. JAMA Psychiatry. 2013 Jan;70(1):31–41.  
180.  Rethorst CD, Toups MS, Greer TL, Nakonezny PA, Carmody TJ, 
Grannemann BD, et al. Pro-inflammatory cytokines as predictors of antidepressant 
effects of exercise in major depressive disorder. Mol Psychiatry. 2013 
Oct;18(10):1119–24.  
181.  Holma KM, Melartin TK, Haukka J, Holma IAK, Sokero TP, Isometsä 
ET. Incidence and predictors of suicide attempts in DSM-IV major depressive disorder: 
a five-year prospective study. Am J Psychiatry. 2010 Jul;167(7):801–8.  
182.  Leng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, Kuchel GA. 
ELISA and Multiplex Technologies for Cytokine Measurement in Inflammation and 
Aging Research. J Gerontol A Biol Sci Med Sci. 2008 Aug;63(8):879–84.  
183.  de Koning L, Liptak C, Shkreta A, Bradwin G, Hu FB, Pradhan AD, et al. 
A multiplex immunoassay gives different results than singleplex immunoassays which 
may bias epidemiologic associations. Clin Biochem. 2012 Jul;45(10-11):848–51.  
184.  de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V. 
Prerequisites for cytokine measurements in clinical trials with   multiplex 
immunoassays. Bmc Immunol. 2009 Sep 28;10.  
185.  Berry LJ, Sheil B, Garratt L, Sly PD, AREST CF. Stability of interleukin 
8 and neutrophil elastase in bronchoalveolar lavage fluid following long-term storage. J 
Cyst Fibros Off J Eur Cyst Fibros Soc. 2010 Sep;9(5):346–50.  
186.  Berent D, Macander M, Szemraj J, Orzechowska A, Galecki P. Vascular 
endothelial growth factor A gene expression level is higher in patients with major 
depressive disorder and not affected by cigarette smoking, hyperlipidemia or treatment 
with statins. Acta Neurobiol Exp (Warsz). 2014;74(1):82–90.  
 
